| Package | Version | Identity | Name/Title | Status | Date |
|---|
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2446  | Influenza A (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2447 | Influenza [Unspecified] (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2448 | Influenza (Tests for unspecified influenza virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2449 | Influenza (Tests for influenza B virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2450 | Influenza (Tests for unspecified influenza virus Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2451 | Influenza (Tests for influenza B virus Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2452 | Influenza (unspecified influenza virus in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2453 | Influenza (influenza B virus in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2454 | Influenza (Tests for unspecified influenza virus by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2455 | Influenza (Tests for influenza B virus by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2456 | Hepatitis B Virus Infection (Tests for Hepatitis B Virus Total Core Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2457 | Hepatitis C Virus Infection (Combination Tests that include hepatitis C virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2458 | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2459 | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid in Blood) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2460 | Borrelia species (Tests by Microscopic Observation) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2461 | Borrelia species (Tests by Microscopic Observation in Blood) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2462 | Spirochetes (Tests by Microscopic Observation) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2463 | Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2464 | CP_ Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2465 | CRE (Tests for Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2466 | CRE (Tests for Proteus spp., Providencia spp., and Morganella spp. by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2467 | CRE (Tests for Enterobacterales species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2468 | CRE (Combination Tests that include Enterobacterales by Culture and Identification) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2469 | Tests for Carbapenem Susceptibility [Meropenem and Doripenem] | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2470 | Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2471 | Proteus spp., Providencia spp., and Morganella spp. (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2473 | Enterobacterales species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2474 | Enterobacterales species [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2475 | Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2476 | Aortic valve stenosis (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2477 | Anotia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2478 | Microtia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2479 | Microtia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2480 | Anotia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2482 | Anophthalmia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2483 | Anophthalmia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2484 | Microphthalmia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2485 | Microphthalmia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2486 | Atrial septal defect (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2487 | Atrial septal defect (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2488 | Fetal Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2489 | Congenital Posterior Urethral Valves (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2490 | Congenital Posterior Urethral Valves (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2491 | Bladder Exstrophy (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2492 | Bladder Exstrophy (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2493 | Encephalocele (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2494 | Fetal Encephalocele (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2495 | Encephalocele (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2496 | Choanal Atresia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2497 | Choanal Atresia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2498 | Cloacal Exstrophy (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2499 | Cloacal Exstrophy (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2500 | Renal Agenesis or Hypoplasia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2501 | Renal Agenesis or Hypoplasia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2502 | Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2503 | Trisomy 13 (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2504 | Fetal Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2505 | Trisomy 13 (Tests for Trisomy 13 Chromosomal Anomaly) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2506 | Galactosemia (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2507 | Galactosemia (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2508 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative] in Blood) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2509 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative] in Blood) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2510 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative] in Blood) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2511 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2512 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2513 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2514 | Galactosemia (Tests for GALT gene allele 1) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2515 | Galactosemia (Tests for GALT gene allele 2) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2516 | Hypospadias (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2517 | Hypospadias (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2518 | Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2519 | Fetal Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2520 | Fetal Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2521 | Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2522 | Trisomy 18 (Tests for Trisomy 18 Chromosomal Anomaly) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2523 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2524 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2525 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2526 | Chlamydia trachomatis Infection (Combination Tests that include Chlamydia trachomatis Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2527 | Chlamydia species [Unspecified] (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2528 | Ventricular septal defect (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2529 | Ventricular septal defect (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2530 | Gonorrhea (Combination Tests that include Neisseria Gonorrhea Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2531 | Intracellular Gram Negative Diplococcus (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2532 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2533 | Congenital Cytomegalovirus (Tests for CMV Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.264 | Viral Hemorrhagic Fever (Disorders) (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.265 | Viral Hemorrhagic Fever (Disorders) (ICD10CM) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.268 | Mumps (Tests for mumps virus IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.272 | Present or Positive Lab Result Value | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.282 | Varicella (Tests for Varicella zoster virus by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.283 | Varicella (Tests for Varicella zoster virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.285 | Encephalitis (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.287 | Varicella (Organism or Substance in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.289 | Carbon Monoxide Poisoning (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.293 | Toxic Effects of Lead (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.297 | Measles (Tests for measles virus Nucleic Acid) | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.299 | Measles (Tests for measles virus IgM Antibody) | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.300 | Meningococcal Disease (Organism or Substance in Lab Results) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.301 | Shigellosis (Tests for Shigella species by Culture and Identification Method) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.304 | Pesticide Related Illness (Disorders) (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.305 | Organisms (Tests by Microscopic Observation in Specimen from Normally Sterile Site by Gram Stain) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.307 | Leptospirosis (Tests for Leptospira IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.308 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.310 | Bacteria (Tests by Culture and Identification Method) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.311 | Viruses (Tests by Culture and Identification Method) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.316 | Rubella (Tests for rubella virus IgM Antibody) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.317 | Shigellosis (Tests for Shigella species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.319 | Fungi (Tests by Culture and Identification Method) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.322 | Pesticide Related Illness (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.326 | Arboviral Disease [Other] (Disorders) (ICD10CM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.329 | Apnea (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.330 | Apnea (ICD10CM) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.333 | Shigellosis (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.335 | Influenza (Tests for influenza A virus by Culture and Identification Method) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.336 | Influenza (Tests for influenza A or B virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.340 | Influenza (influenza A or B virus in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.341 | Campylobacteriosis (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.342 | Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.343 | Campylobacteriosis (Tests for Campylobacter species Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.344 | Campylobacteriosis (Tests for Campylobacter species Antigen) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.349 | Hepatitis A (Tests for hepatitis A virus IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.353 | Diarrhea (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.356 | HIV Infection (Organism or Substance in Lab Results) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.359 | Botulism (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.362 | Hansen’s Disease (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.365 | Silicosis (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.366 | Silicosis (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.371 | Cryptosporidiosis (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.372 | Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.375 | Cyclosporiasis (Organism or Substance in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.376 | Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.379 | Giardiasis (Tests for Giardia species Nucleic Acid) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.384 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.386 | Vibriosis (Organism or Substance in Lab Results) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.388 | Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.390 | Trichinellosis (Tests for Trichinella species Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.395 | Syphilis (Disorders) (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.396 | Syphilis (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.398 | Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.399 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.40 | STEC Infection (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.400 | Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.401 | Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.403 | Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.405 | Hantavirus Infection and Diseases (Disorders) (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.407 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.408 | Hepatitis B Virus Infection (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.422 | Tuberculosis (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.427 | STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.43 | Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.436 | Coccidioidomycosis (Tests for Coccidioides species IgM Antibody) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.437 | Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.438 | Coccidioidomycosis (Tests for Coccidioides species Antigen) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.44 | Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.445 | Legionellosis (Tests for Legionella species Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.446 | Legionellosis (Tests for Legionella species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.451 | Tuberculosis (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.460 | HIV Infection or AIDS (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.464 | Malaria (Tests for Plasmodium species Nucleic Acid) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.468 | Leptospirosis (Tests for Leptospira Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.471 | Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.472 | Leptospirosis (Tests for Leptospira Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.476 | Babesia species (Tests by Microscopic Observation in Blood) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.478 | Anthrax (Tests for Bacillus anthracis by Culture and Identification Method) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.479 | Anthrax (Tests for Bacillus anthracis Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.48 | Salmonellosis (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.480 | Anthrax (Tests for Bacillus anthracis Antigen) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.481 | Anthrax (Tests for Bacillus anthracis Antibody) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.494 | Ehrlichiosis (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.496 | Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen]) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.500 | Q Fever (Tests for Coxiella burnetii Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.505 | Toxic Shock Syndrome (TSS) (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.507 | Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.512 | Brucellosis (Tests for Brucella species Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.515 | Brucellosis (Tests for Brucella species Antibody [Quantitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.516 | Brucellosis (Organism or Substance in Lab Results) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.519 | Dengue Virus Infection (Tests for dengue virus Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.523 | Dengue Virus Infection (Tests for dengue virus Antigen) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.524 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative]) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.525 | Dengue Virus Infection (Tests for dengue virus IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.527 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative]) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.530 | Borrelia species (Tests for Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.531 | Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.532 | Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.534 | Smallpox (Organism or Substance in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.542 | Spotted Fever Rickettsiosis (Organism or Substance in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.548 | St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative]) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.550 | Syphilis (Tests for Treponema pallidum Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.553 | Anaplasma species (Tests by Microscopic Observation) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.555 | Yellow Fever (Tests for yellow fever virus Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.557 | Yellow Fever (Tests for yellow fever virus Antibody [Quantitative]) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.56 | Diarrhea (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.560 | West Nile Virus Infection (Tests for West Nile virus Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.569 | Plague (Tests for Yersinia pestis Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.575 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.576 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antigen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.577 | Arboviral Disease [Other] (Tests for Arbovirus [Other] IgM Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.578 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Quantitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.579 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Qualitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.58 | Pertussis (Tests for Bordetella pertussis Nucleic Acid) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.580 | Arboviral Disease [Other] (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.581 | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.584 | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus IgG Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.586 | Viral Hemorrhagic Fever (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.595 | Tularemia (Tests for Francisella tularensis Nucleic Acid) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.598 | Tularemia (Tests for Francisella tularensis Antibody) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.6 | Diphtheria (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.605 | Organisms (Tests by Microscopic Observation by Acid Fast Stain) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.606 | Tuberculosis (Organism or Substance in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.614 | Pertussis (Tests for Bordetella pertussis Toxin Antibody) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.621 | Inspiratory Whoop (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.632 | Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.645 | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.648 | Vomiting (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.650 | Jaundice (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.652 | Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.660 | Hypertonia [Excluding Congenital Hypertonia] (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.662 | Chest Pain (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.663 | Erythema Nodosum (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.664 | Congenital Zika Syndromes (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.665 | Congenital Zika Syndromes (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.666 | Guillain Barré syndrome (Disorders) (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.668 | Rash (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.671 | Fever (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.672 | Arthralgia (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.673 | Arthralgia (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.674 | Conjunctivitis (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.675 | Conjunctivitis (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.676 | Pregnant (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.677 | Postpartum (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.678 | Postpartum (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.679 | Hearing Loss (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.680 | Abdominal Pain (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.681 | Abdominal Pain (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.686 | Erythema Multiforme (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.687 | Myalgia (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.689 | Periorbital Edema (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.691 | Eosinophilia (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.692 | Eosinophilia (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.70 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi by Culture and Identification Method) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.702 | Weight Loss (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.705 | Syphilis (Tests for Treponemal or Non Treponemal Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.709 | Cough [Non Productive] (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.71 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi Nucleic Acid) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.711 | Wound Infection (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.712 | Pneumonia (ICD10CM) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.713 | Sepsis [Septicemia] [Unspecified Organism] (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.714 | Sepsis [Septicemia] [Unspecified Organism] (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.715 | Meningitis (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.717 | Cellulitis (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.718 | Cellulitis (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.719 | Myositis [Unspecified Cause] (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.720 | Myositis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.721 | Otitis Media (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.722 | Otitis Media (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.723 | Otitis Externa (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.724 | Otitis Externa (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.727 | Acute Upper Respiratory Illness (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.728 | HIV Infection (Tests for HIV Nucleic Acid [Qualitative]) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.730 | HIV Infection (Tests for HIV Antibody) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.733 | Perinatal Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.741 | Hepatitis B Immune Globulin (RXNORM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.744 | Coccidioidomycosis (Tests for Coccidioides species IgG Antibody) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.746 | Treponema pallidum (Tests by Microscopic Observation) | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.747 | Penicillin G [Benzathine] [Injectable] [Bicillin] (RXNORM) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.750 | Chest Pain (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.755 | Acute Upper Respiratory Illness (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.756 | Purpura (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.757 | Muscle Spasms (ICD10CM) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.758 | Muscle Spasms (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.762 | Mumps (Test Panels for mumps virus IgM IgG Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.763 | Parotitis [Unspecified Cause] (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.764 | Mumps (Tests for mumps virus IgG Antibody) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.765 | Aseptic Meningitis (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.766 | Encephalitis (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.767 | Hearing Loss (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.770 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.773 | Invasive Haemophilus influenzae Disease (Tests for Haemophilus influenzae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.777 | Mastitis (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.779 | Pancreatitis (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.780 | Pancreatitis (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.782 | Rubella (Test Panels for rubella virus IgM IgG Antibody) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.785 | Opioid Overdose and Poisoning (Tests for Opioids [Qualitative]) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.789 | Purpura (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.79 | Campylobacteriosis (Disorders) (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.792 | Novel Influenza A Virus Infection (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.793 | Novel Influenza A Virus Infection (Disorders) (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.794 | Sore Throat (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.795 | Influenza (influenza A virus in Lab Results) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.796 | Influenza (Novel influenza A virus in Lab Results) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.797 | Influenza (Tests for influenza A or B virus by Culture and Identification Method) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.798 | Influenza (Tests for influenza A virus Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.799 | Influenza (Tests for influenza A virus Antigen) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.802 | Influenza (Tests for Novel influenza A virus Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.803 | Tests by Microscopic Observation in Tissue by H&E or PAS Stain | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.808 | Headache (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.809 | Headache (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.810 | Backache (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.811 | Backache (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.815 | NU_Anaplasmosis (Tests for Anaplasma species Antibody [Qualitative]) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.816 | Rubella (Tests for rubella virus IgG Antibody [Ratio] in Serum) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.818 | Measles (Tests for measles virus IgG Antibody [Ratio] in Serum) | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.820 | Rubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.822 | Pneumoconiosis (Unspecified) (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.823 | Pneumoconiosis (Unspecified) (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.824 | Computerized Tomography of Chest (Imaging) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.830 | Poliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.835 | Lead in Blood (Disorders) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.836 | Lead in Blood (Disorders) (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.839 | Acid Fast Bacilli (Organism or Substance in Lab Results) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.841 | Tuberculosis (Interferon Gamma Release Assays) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.842 | Tests by Microscopic Observation in Tissue | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.844 | Tuberculosis (Second Line Drugs for Treatment) (RXNORM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.846 | SARS (Tests for SARS_CoV by Culture and Identification Method) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.847 | SARS (Tests for SARS_CoV Nucleic Acid) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.86 | Hemolytic Uremic Syndrome (HUS) (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.864 | Nausea (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.865 | Confusion (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.867 | Dyspnea (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.869 | Loss of Consciousness (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.87 | Thrombotic Thrombocytopenic Purpura (TTP) (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.875 | SARS (Organism or Substance in Lab Results) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.878 | MERS (Tests for MERS_CoV Nucleic Acid) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.88 | Hemolytic Uremic Syndrome (HUS) (Disorders) (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.881 | Difficulty Breathing (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.884 | Tests by Microscopic Observation in Blood | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.889 | Hantavirus Infection (Tests for Hantavirus IgM IgG Total Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.892 | Organisms (Tests by Microscopic Observation in Tissue by Acid Fast Stain) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.895 | Rhinorrhea (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.896 | Tests by Microscopic Observation in Blood Smear | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.897 | Dengue Virus Infection (Test Panels for dengue virus IgM IgG Antibody) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.9 | Xray of Chest (Imaging) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.90 | Cough (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.900 | Organisms (Tests by Microscopic Observation) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.902 | Acute Renal Failure [Unspecified Cause] (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.907 | Arthritis [Unspecified Cause] (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.91 | Cough (SNOMED) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.910 | Epididymitis [Unspecified Cause] (SNOMED) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.911 | Epididymitis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.914 | Osteomyelitis [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.915 | Osteomyelitis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.918 | Spondylitis [Unspecified Cause] (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.919 | Arthritis [Unspecified Cause] (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.92 | Thrombotic Thrombocytopenic Purpura (TTP) (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.927 | Thrombocytopenia [Unspecified Cause] (ICD10CM) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.928 | Bleeding [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.930 | ECG Abnormalities [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.931 | Hematemesis [Unspecified Cause] (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.932 | Hematemesis [Unspecified Cause] (ICD10CM) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.934 | Hematuria [Unspecified Cause] (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.935 | Hemoptysis (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.937 | Gastrointestinal Hemorrhage [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.942 | Petechiae [Non Traumatic] (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.952 | Thrombocytopenia [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.956 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.957 | Regional Lymphadenitis [Including Bubo] (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.958 | Regional Lymphadenitis (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.96 | Salmonellosis [Salmonella Species and Subspecies] (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.963 | Arboviral Disease [Other] (Disorders) (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.965 | Proteinuria [Unspecified Cause] (ICD10CM) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.969 | Proteinuria [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.970 | Bulbar Weakness (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.971 | Bulbar Weakness (ICD10CM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.976 | Dysphagia (SNOMED) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.978 | Impaired Respiration [Unspecified Cause] (SNOMED) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.979 | Botulism (Organism or Substance in Lab Results) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.98 | Shigellosis (Disorders) (SNOMED) | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.989 | Tests for Mycobacterium species by Culture and Identification Method | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.991 | Rifampin (RXNORM) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.994 | Organisms (Tests for Nucleic Acid) | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.998 | Shigellosis (Tests for Enteroinvasive E. coli Nucleic Acid) | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.999 | Chlamydia species (Organism or Substance in Lab Results) | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.109 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.110 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.112 | Pressure Injury Deep Tissue | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.113 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.119 | Inpatient Falls | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.120 | Major Injuries | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.122 | Inpatient Falls | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.125 | Bleeding at Non Critical Site | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.130 | Anticoagulants for VTE Prophylaxis | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.131 | Anticoagulants for Indications Other than VTE Prophylaxis | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.135 | Bleeding at Critical Site | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.143 | Bleeding at Critical Site | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.144 | Bleeding at Critical Site | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.145 | Bleeding at Non Critical Site | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.146 | Bleeding at Non Critical Site | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.160 | Abdominal or Pelvic CT Scan with Contrast | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.163 | Ultrasound of Lower Extremities | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.164 | Ultrasound of Lower Extremities | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.165 | Ultrasound of Lower Extremities | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.171 | Inpatient Falls | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.183 | Anti Factor Xa Assay | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.187 | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.188 | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.190 | Intra Aortic Balloon Pump | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.191 | Intra Aortic Balloon Pump | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.193 | Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.194 | Pressure Injury Deep Tissue Diagnoses | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.196 | Pressure Injury Stage 2, 3, 4, or Unstageable Diagnoses | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.197 | Present on Admission or Clinically Undetermined | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.198 | Not Present On Admission or Documentation Insufficient to Determine | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.1 | DEXA Dual Energy Xray Absorptiometry, Bone Density | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.11 | Bladder Cancer Staging Ta for Urology Care | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.12 | Bladder Cancer staging T1 for Urology Care | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.13 | Bladder Cancer staging Tis for Urology Care | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.15 | Carcinoma of urinary bladder, superficial | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.16 | Injection Leuprolide Acetate | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.17 | High grade bladder cancer Ta for Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.18 | Immunocompromised state for Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.19 | Systemic chemotherapy for urology care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.2 | Bladder Cancer in Situ | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.20 | Corticosteroids for patients receiving Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.21 | Calcineurin inhibitors for patients receiving Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.23 | Immunomodulators for patients undergoing Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.24 | Monoclonal antibody for patient undergoing Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.28 | Radiotherapy for patients undergoing Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.29 | Plasmacytoid cell, morphologic abnormality for urology care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.3 | Bladder Cancer in Situ | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.30 | Sarcomatoid, morphologic abnormality for Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.31 | Micropapillary, morphologic abnormality, for Urology Care | active | 2017-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.32 | Immunosuppressive Drugs for Urology Care | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.38 | DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.39 | Mixed histology urothelial cell carcinoma for Urology Care | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.4 | BCG Bacillus Calmette Guerin, Tice | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.40 | Cystectomy for Urology Care | active | 2017-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.44 | Unavailability of Bacillus Calmette Guerin for urology care | active | 2017-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.45 | Bladder Cancer for Urology Care | active | 2017-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.48 | Androgen deprivation therapy for Urology Care | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.5 | BCG Bacillus Calmette Guerin, Connaught | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52 | BCG Bacillus Calmette Guerin for Urology Care | active | 2020-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.53 | Cystectomy for Urology Care | active | 2018-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.54 | Acute Tuberculosis for Urology Care | active | 2018-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.55 | Cystectomy for Urology Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.56 | Active Tuberculosis for Urology Care | active | 2018-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.57 | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.58 | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.59 | Hospital Services for Urology | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.6 | Peripheral DXA Scan | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.60 | Chemotherapy Agents for Advanced Cancer | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.8 | Tuberculosis Diagnosis Prior to Urology Care | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.9 | Leukemia Diagnosis Prior to Urology Care | active | 2016-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.13 | Preventative Clinical Encounters | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.14 | Intensive Lifestyle Interventions | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.15 | Intensive Lifestyle Interventions | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.16 | Intensive Lifestyle Interventions | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.17 | Intensive lifestyle interventions | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.21 | Outpatient Clinical Encounters | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.22 | Outpatient Clinical Encounters | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.23 | Outpatient Clinical Encounters | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.24 | Outpatient Clinical Encounters | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.25 | Reason for No Intensive Lifestyle Intervention | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.27 | Type 2 Diabetes Diagnoses | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.28 | Type 2 Diabetes Diagnoses | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.29 | Type 2 Diabetes Diagnoses | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.30 | Prediabetes HbA1c Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.31 | Prediabetes HbA1c Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.32 | Prediabetes HbA1c Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.33 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.34 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.35 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.36 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.37 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.38 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.4 us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.3 | Malignant Intracranial Neoplasm Group | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.31 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.32 | Healthcare Agent and Power of Attorney Documentation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.33 | Advance Directive Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.34 | Advance Directive Documentation | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.35 | Advance Directive Documentation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.36 | Portable Medical Order(s) Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.37 | Portable Medical Order(s) Documentation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.38 | Advance Care Planning Discussion Documentation | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.4 | Thrombolytic medications | active | 2021-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.40 | Advance Care Planning Documentation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.41 | Advance Care Planning Documentation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.42 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.43 | Advance Directive Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.45 | Advance Care Planning Documentation | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.46 | Advance Care Planning Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.47 | Portable Medical Order(s) Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.48 | Portable Medical Order(s) Documentation | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.49 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.5 | Allergy to thrombolytics | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.50 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.51 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.52 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.53 | Intervention for Positive Housing Instability Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.54 | Intervention for Positive Housing Instability Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.55 | Intervention for Positive Homelessness Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.56 | Intervention for Positive Homelessness Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.57 | Non Invasive Oxygen Therapy Device Codes | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.58 | Goals, preferences, and priorities for medical treatment | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.6 | Thrombolytics Adverse Event | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.7 | Intraspinal surgery | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.8 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.9 | Utility Insecurity Diagnosis | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1176.58 | Food Insecurity Screening Positive | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.1 | Ezetimibe Therapy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.10 | Antihypertensive Medications | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.100 | Allergy or Intolerance to ACE Medication | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.101 | Allergy or Intolerance to ARB Medication | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.102 | Chronic Kidney Disease Stage 1 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.103 | Chronic Kidney Disease Stage 2 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.104 | Chronic Kidney Disease Stage 3 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.105 | Chronic Kidney Disease Stage 4 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.106 | Chronic Kidney Disease Stage 5 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.107 | ICD10 CM Chronic Kidney Disease Stage 1 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.108 | ICD10 CM Chronic Kidney Disease Stage 2 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.111 | AHA GWTG Chronic Kidney Disease Stage 2 | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.112 | ICD10 CM Chronic Kidney Disease Stage 3 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.113 | ICD10 CM Chronic Kidney Disease Stage 4 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.114 | ICD10 CM Chronic Kidney Disease Stage 5 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.115 | AHA GWTG Chronic Kidney Disease Stage 1 | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.116 | AHA GWTG Chronic Kidney Disease Stage 3 | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.117 | AHA GWTG Chronic Kidney Disease Stage 4 | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.118 | SNOMED CT Atrial Fibrillation | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.119 | ICD10 CM Atrial Fibrillation | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.121 | AHA GWTG Atrial Fibrillation | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.123 | SNOMED CT Hyperlipidemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.124 | ICD10 CM Hyperlipidemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.125 | AHA GWTG Hyperlipidemia | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.126 | SNOMED CT Hypertriglyceridemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.127 | ICD10 CM Hypertriglyceridemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.129 | AHA GWTG Hypertriglyceridemia | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.130 | SNOMED CT Gestational Diabetes | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.131 | ICD10 CM Gestational Diabetes | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.132 | AHA GWTG Gestational Diabetes | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.133 | SNOMED CT Hyperglycemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.134 | ICD10 CM Hyperglycemia | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.135 | AHA GWTG Hyperglycemia | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.136 | SNOMED CT Nonobstructive CAD | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.137 | ICD10 CM Nonobstructive Coronary Artery Disease | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.138 | AHA GWTG Nonobstructive coronary artery disease | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.139 | AHA GWTG Anti Obesity Pharmacotherapy | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.15 | Non Tobacco Smoking Product User | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.16 | Antihypertensive Fixed Dose Combination Medications | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.2 | PCSK9 Inhibitors | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.20 | CCB and Thiazide and Thiazide Like Diuretics | active | 2021-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.21 | Referral to cardiac rehab | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.22 | Cardiac Rehabilitation | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.25 | 2 Hour Blood Glucose Test | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.26 | NYHA Functional Classification | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.27 | ARNI Therapy | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.29 | MRA Therapy | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.3 | Cholesterol non HDL Laboratory Test | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.30 | SGLT2 Inhibitors | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.31 | Heart Transplant | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.32 | Heart Transplant | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.33 | Heart Transplant | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.34 | Allergy to MRA Therapy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.35 | Aspirin or Clopidogrel | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.39 | Cardiac Rehabilitation | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.4 | Hypothyroidism | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.40 | Cardiac Rehabilitation | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43 | SGLT2 Ingredients | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.44 | MRA Ingredients | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.49 | Minnesota Living with Heart Failure Questionnaire | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.5 | Hypothyroidism | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.50 | Kansas City Cardiomyopathy Questionnaire | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.51 | Cardiac Pacer | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.52 | Cardiac Pacer | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.53 | Cardiac Pacer | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.54 | Heart Transplant Complications | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.55 | Heart Transplant Complications | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.56 | Heart Transplant Complications | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.57 | Left Ventricular Assist Device Complications | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.58 | Left Ventricular Assist Device Complications | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.59 | Left Ventricular Assist Device Placement | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.6 | Hypothyroidism | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.60 | Left Ventricular Assist Device Placement | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.61 | Left Ventricular Assist Device Placement | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.62 | Left Ventricular Assist Device Placement | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.63 | Heart Transplant | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.65 | Cardiac Pacer | active | 2022-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.66 | Diastolic Heart Failure | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.67 | Diastolic Heart Failure | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.68 | Diastolic Heart Failure | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.69 | Allergy to SGLT2 Inhibitors | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.7 | Anorexia Nervosa | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.70 | Intolerance to SGLT2 Inhibitors | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71 | Intolerance to MRA Therapy | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.72 | ARNI Ingredient | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.73 | Mitral Stenosis | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.74 | Mitral Stenosis | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.75 | Mitral Stenosis | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.76 | Mechanical Prosthetic Heart Valve | active | 2022-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.77 | Mechanical Prosthetic Heart Valve | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.78 | Mechanical Prosthetic Heart Valve | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.79 | Mechanical Prosthetic Heart Valve in Situ | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.8 | Anorexia Nervosa | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.82 | Systolic Heart Failure | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.83 | Systolic Heart Failure | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.84 | Systolic Heart Failure | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.85 | Carotid Intervention | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.86 | Serum Creatinine | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.87 | Urine Creatinine | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.88 | Urine Albumin | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.9 | Anorexia Nervosa | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.90 | Non Steroidal Mineralcorticoid Receptor Antagonist | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.91 | Glucagon like peptide 1 medications | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.96 | AHA GWTG Long COVID19 | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.97 | AHA GWTG Long COVID19 SNOMEDCT | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.98 | AHA GWTG Long COVID19 ICD10CM | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.1 | Wound internal item and/or body structure visible value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.11 | Wound exudate appearance value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.12 | Wound exudate color value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.13 | Exudate odor value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.14 | Wound anatomic location value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.16 | Skin temperature value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.17 | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.18 | Skin turgor value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.19 | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.2 | Periwound condition value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.20 | Skin moisture value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.3 | Wound Type Etiology value set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.4 | Wound episode value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.6 | Wound bed appearance value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.60 | Wound type reference set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.7 | Wound bed color value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.74 | Nonverbal pain indicators reference set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.76 | Pain associated signs and symptoms reference set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.77 | Pain body location reference set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.8 | Wound edge description value set (foundation metadata concept) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.80 | Pain quality reference set | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.81 | Pain speed of onset reference set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.9 | Presence absence value set (foundation metadata concept) | active | 2018-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1 | Common drug substances for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.2 | Common drug classes for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.3 | Common dietary substances for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.4 | Common environmental substances for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.5 | Common refutations for substance causes for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7 | Common substances for allergy and intolerance documentation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8 | Common substances for allergy and intolerance documentation including refutations | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.10 | NHSNCriterionOfDiagnosisCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.11 | NHSNCriterionOfDiagnosisCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.12 | NHSNInfectionConditionCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.13 | NHSNInfectionConditionCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.14 | NHSNInfectionTypeCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.15 | NHSNInfectionTypeCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.16 | NHSNInfectionFirstReportedSource(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.17 | NHSNInfectionFirstReportedSource(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.18 | NHSNLOS/MENDischargeDisposition(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.19 | NHSNLOS/MENDischargeDisposition(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.20 | NHSNPopulationSummaryReportTypeCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.21 | NHSNPopulationSummaryReportTypeCode(LOINC) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.22 | NHSNSameDayOutcomeMeasure(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.23 | NHSNSameDayOutcomeMeasure(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.24 | NHSNSignificantPathogenCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.25 | NHSNSignificantPathogenCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.26 | NHSNSpinalFusionApproachCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.27 | NHSNSpinalFusionApproachCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.28 | NHSNVascularAccessTypeCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.29 | NHSNVascularAccessTypeCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.30 | NHSNVascularSpecimenCollectionSite(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.31 | NHSNVascularSpecimenCollectionSite(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.38 | Blood Glucose Laboratory and Point of Care Tests | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58 | Diabetes Medications | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.6 | NHSNPathogenCodeARO | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.62 | Lab Tests for Clostridioides difficile | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.63 | Bacterial and Fungal Blood Culture Tests | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.7 | NHSNRoleOfPerformerCode(CDCNHSN) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.74 | Enteral Medication Route | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.75 | Intravenous Medication Route | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76 | Fidaxomicin | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77 | Vancomycin | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78 | Metronidazole | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79 | Fidaxomicin, Vancomycin, and Metronidazole | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.8 | NHSNRoleOfPerformerCode(SNOMEDCT) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85 | Baloxavir | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86 | Peramivir | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87 | Zanamivir | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.88 | Digestive, Intramuscular, Intravenous Route of Administration | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.89 | Maternal Diagnoses | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.9 | NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy) | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90 | NHSN LTC AU Antimicrobial Agents | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.91 | Long Term Care Discharge Disposition | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.94 | NHSNNeurogenicBladder | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.95 | NHSNSpinalCordInjury | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1139 | S4G Hyperlipidemia | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1291 | S4G Cardiomyopathy | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1292 | S4G Tricuspid valve disorder | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1293 | S4G Pompe disease | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1294 | S4G Malignant hyperthermia | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1295 | S4G Malignancy | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1297 | S4G Intestinal polyp | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1298 | S4G Hamartoma | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1299 | S4G Diabetes mellitus | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1300 | S4G Muscular dystrophy and weakness | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1325 | S4G Hamartoma and S4G Intestinal Polyp | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1326 | S4G Malignancy and S4G Intestinal Polyp | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1344 | Tests for Neisseria gonorrhoeae of unspecified site reported by presence | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1352 | Body weight | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354 | Cefixime preparations for oral administration | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1358 | Beta lactam medicinal product SNOMED | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370 | Beta lactam ingredients for allergy determination RXNORM | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.147 | SCIP Major Surgical Procedure | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158 | Multiple Myeloma Regimen Drugs | active | 2019-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 | Opioids, All | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3483 | Financial Insecurity Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3484 | Food Insecurity Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3485 | Health Literacy Screening Assessments Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3486 | Homelessness Screening Assessments Questions | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3487 | Housing Instability Screening Assessments Questions | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3488 | Less Than High School Education Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3519 | Health Insurance Coverage Status Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3520 | Inadequate Housing Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393 | Hypoglycemics Severe Hypoglycemia | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 | Hypoglycemics Treatment Medications | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436 | Gentamicin medications | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437 | Azithromycin medications | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448 | Lidocaine | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4466 | Pharyngeal specimens | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4467 | Urogenital & Anorectal Specimens | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469 | Cabotegravir Injectable Products | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470 | Emtricitabine oral for HIV PrEP | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4474 | HIV Laboratory Based Tests | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502 | Ceftriaxone all code types | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491 | Medium Dose ICS Formoterol Preparations | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495 | ICS LABA LAMA Preparations | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.788 | Social Determinants of Health Conditions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.789 | Social Determinants of Health Procedures | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.790 | Social Determinants of Health Service Requests | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93 | CPIC RxNORM abacavir SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94 | CPIC RxNORM allopurinol SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95 | CPIC RxNORM amitriptyline SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96 | CPIC RxNORM atazanavir SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97 | CPIC RxNORM atomoxetine SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99 | CPIC RxNORM capecitabine SCDG | active | 2019-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.1 | Mechanical Complications Related To Hip and Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.10 | Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.11 | Procedures Resulted From Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12 | Opioid (Oral Tablets and Patches only) | active | 2019-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.13 | Comorbidity Risk Factors | active | 2020-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.14 | Treatment of Hemorrhage or Hematoma | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.15 | General Surgery | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.17 | Coagulation Disorder Conditions | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.18 | Acute Respiratory Failure | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19 | Anticoagulant Medications | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.2 | Fracture Exclusions For Hip And Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20 | Anticoagulant Medications, Oral | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21 | Anticoagulant Medications, Injection | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.28 | Active Bleeding | active | 2020-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29 | Fall Risk Increasing Drugs (FRIDs) | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.3 | Pulmonary Embolism Complications Related To Hip and Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.30 | Fall Risk Factors | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.32 | Total Hip Arthroplasty Surgery | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.33 | Total Knee Arthroplasty Surgery | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.34 | AbnormalityOfGaitAndMobility | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.35 | Assymetry Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.36 | Hemiplegia Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.37 | Leg Weakness Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.38 | Osteopenia Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.39 | Stroke Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.4 | Sepsis Complications Related To Hip and Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.40 | Vestibular Symptoms | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41 | TricyclicAntidepressants | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42 | Benzodiazepines | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43 | LoopDiuretics | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44 | Antiepileptics | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45 | Antipsychotics | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46 | Opioid Medications | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.47 | Imaging Related to VTE | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48 | Anticoagulant Medication | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.49 | VTE Diagnoses | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.5 | Nonprimary Total Hip, Total Knee Replacement | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50 | Bisphosphonate Therapy | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.51 | VTE Symptoms | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.52 | Oncology Critical Care Units | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.53 | Provider Types | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.56 | FOBT_Lab | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.57 | Colorectal Screening | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.58 | Screening Mammogram (CPT) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.59 | Screening Mammogram (LOINC) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.6 | Pneumonia Complications Related To Hip and Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.60 | Screening Mammogram (SNOMEDCT) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.61 | Screening Mammogram (Grouping) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.62 | Diagnostic Mammography (CPT) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.63 | Diagnostic Mammography (LOINC) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.64 | Diagnostic Mammography (SNOMEDCT) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.65 | Diagnostic Mammography | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.66 | Breast Cancer Biopsy and Surgical Excision | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.67 | BI_RADS Categories 0, 4, and 5 | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.68 | BI_RADS Categories 1, 2, and 3 | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.7 | Malignant Neoplasm Complications Related To Hip and Knee Procedures | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.8 | Periprosthetic Joint Infection/Wound Infection and Other Wound Complications | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.9 | Procedures Resulted From Periprosthetic Joint Infection/Wound Infections | active | 2019-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101 | Local Anesthetics | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102 | Ophthalmic Epinephrines | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103 | Inhaled Epinephrines | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104 | Clopidogrels | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105 | Cytochrome P450 2C19 inhibitors | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106 | Cytochrome P450 2C9 inhibitors | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107 | Aspirin Ingredient and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109 | Oral Anticoagulant Ingredients and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110 | Corticosteroid Ingredients and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111 | Antidepressant Ingredients and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112 | PPI and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113 | Antiplatelet Ingredients and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114 | NSAIDs Ingredients and Risk of GI Bleeding | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.115 | Kratom containing compounds | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117 | Clopidogrel Ingredients and Risk of GI Bleeding | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.121 | Gastrointestinal bleeding episode and Risk of GI Bleeding 1 | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.122 | Gastrointestinal bleeding episode and Risk of GI Bleeding 2 | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.123 | Gastrointestinal bleeding episode and Risk of GI Bleeding | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24 | Oxycodones | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1217.2 | TESTSemanticBitsValueSet | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1 | Bronchiectasis Disorder SNOMED | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.10 | Interstitial Lung Disease ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.100 | Occupational Therapy Procedure HCPCS | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.101 | Occupational Therapy Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.102 | Speech Language Therapy Procedure HCPCS | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.103 | Speech Language Therapy Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.104 | Home Health Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.105 | Intermittent Skilled Nursing Home Health Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.106 | pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.107 | Breathing Test Procedure During Sleep | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.108 | Ambulance Transport Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.109 | Prefabricated Spinal Orthotic Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.11 | Interstitial Lung Disease SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.110 | Custom Fitted Spinal Orthotic Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.111 | Custom Fabricated Spinal Orthotic Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.112 | Orthotic Device Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.113 | Spinal Orthotic Device or Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.115 | Spine or Neck Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.116 | Spine or Neck Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.117 | Spine or Neck Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.118 | Total Electric Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.119 | Hypoventilation Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.12 | Interstitial Lung Disease | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.120 | Hypoventilation Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.121 | Hypoventilation Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.122 | Respiratory Assist Device Qualifying Condition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.123 | Apnea Hypopnea Index Rate Measurement | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.124 | Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) Measurement | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.125 | Maximal Inspiratory Pressure Measurement | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.126 | Forced Vital Capacity (FVC) Measurement by Spirometry | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.127 | Oxygen Saturation Measurement At Rest | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.128 | Respiratory Assist Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.129 | Respiratory Assist Device Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.13 | Cystic Fibrosis Lung Disease ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.130 | Home Oxygen Therapy Accessory | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.131 | Forced Vital Capacity (FVC) Measurement Prediction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.132 | Oxygen Saturation Laboratory Test and Setting for Breathing Assistance Device Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.133 | Respiratory Disturbance Index | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.134 | Sleep Related Symptom for Positive Airway Pressure Device Use Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.135 | Past Medical History Condition Related to Need for Positive Airway Pressure Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.136 | Home or Facility Care Location | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.137 | Fracture of Bone Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.138 | Fracture of Bone Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.139 | Fracture of Bone Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.14 | Cystic Fibrosis Lung Disease SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.140 | Severe Obesity Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.141 | Severe Obesity Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.142 | Severe Obesity Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.143 | Transfer from Bed Impairment SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.144 | Bed Confinement Impairment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.145 | Transfer from Bed Impairment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.146 | Ability to Safely Sit in Chair or Wheelchair Impairment SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.147 | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.148 | Ability to Safely Sit in Chair or Wheelchair Impairment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.149 | Fall or Fall Risk from Wheelchair or Stretcher SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.15 | Cystic Fibrosis Lung Disease | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.150 | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.152 | Muscle, Tendon or Joint Contracture Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.153 | Muscle, Tendon or Joint Contracture Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.154 | Muscle, Tendon or Joint Contracture Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.155 | Muscle Weakness or Myasthenia Gravis Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.156 | Muscle Weakness or Myasthenia Gravis Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.158 | Myocardial Infarction Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.159 | Myocardial Infarction Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.16 | Neoplasm of Lung or Trachea Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.160 | Myocardial Infarction Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.161 | Amputation Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.162 | Amputation Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.164 | Lower Extremity Deep Vein Thrombosis Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.165 | Lower Extremity Deep Vein Thrombosis Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.167 | Spinal Cord Injury or Paralysis Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.168 | Spinal Cord Injury or Paralysis Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.169 | Spinal Cord Injury or Paralysis Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.17 | Neoplasm of Lung or Trachea Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.170 | Demyelinating Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.171 | Demyelinating Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.172 | Demyelinating Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.173 | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.174 | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.176 | Wound Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.177 | Wound Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.178 | Wound Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.179 | Danger to Self or Others Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.18 | Neoplasm of Lung or Trachea Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.180 | Danger to Self or Others Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.181 | Danger to Self or Others Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.182 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.183 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.184 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.185 | Pain on Movement or Joint Pain Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.186 | Pain in Joint Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.187 | Pain on Movement or Joint Pain Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.188 | Non Emergency Ambulance Transport Reason | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.189 | Osteoarthritis Disorder SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.19 | Secondary Erythrocytosis Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.190 | Osteoarthritis Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.191 | Osteoarthritis Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192 | Immunosuppressive Medication RxNorm | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193 | Medication Supporting Immunosupressive Medication RxNorm | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.194 | Non Emergency Ambulance Transport Qualifying Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197 | Turalio | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.198 | Hepatic Medical History | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.2 | Bronchiectasis Disorder ICD10CM | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.20 | Secondary Erythrocytosis Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.21 | Secondary Erythrocytosis Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.22 | Acute or Chronic Heart Failure Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.23 | Acute or Chronic Heart Failure Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.24 | Acute or Chronic Heart Failure Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.25 | Home Oxygen Therapy Qualifying Condition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.26 | Device Use Patient Activity Level | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.27 | Portable Liquid Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.28 | Stationary Liquid Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.29 | Sleep Apnea or Breathing Related Sleep Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.3 | Bronchiectasis Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.30 | Sleep Apnea or Breathing Related Sleep Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.31 | Sleep Apnea or Breathing Related Sleep Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.32 | Positive Airway Pressure Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.33 | Diabetes Mellitus Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.34 | Diabetes Mellitus Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.35 | Diabetes Mellitus Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.36 | Restrictive Lung Disease SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.37 | Restrictive Lung Disease ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.38 | Restrictive Lung Disease | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.39 | Chest Wall Deformity Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.4 | Chronic Obstructive Lung Disease (COPD) ICD10CM | active | 2020-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.40 | Chest Wall Deformity Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.41 | Chest Wall Deformity Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.42 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.43 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.44 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.45 | Chronic Respiratory Failure Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.46 | Chronic Respiratory Failure Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.47 | Chronic Respiratory Failure Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.48 | Ventilator Therapy Qualifying Condition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.49 | Ventilator Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.5 | Chronic Obstructive Lung Disease SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.50 | Fixed Height Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.51 | Variable Height Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.52 | Semi electric Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.53 | Heavy Duty Extra Wide Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.54 | Extra Heavy Duty Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.55 | Hospital Bed Trapeze Accessory Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.56 | Hospital Bed Cradle Accessory Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.57 | Hospital Bed Side Rail or Safety Enclosure Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.58 | Hospital Bed Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.59 | Intermittent Urinary Catheter or Urological Supply for Intermittent Urinary Catheter Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.6 | Chronic Obstructive Lung Disease (COPD) | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.60 | Indwelling Urinary Catheter Supply or Urological Supply for Indwelling Urinary Catheter Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.61 | Urinary Collection and Irrigation System Device or Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.62 | External Catheter or Urinary Collection Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.63 | Miscellaneous Urinary Catheter Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.64 | Urinary Incontinence Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.65 | Urinary Incontinence ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.66 | Urinary Incontinence Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.67 | Chronic Urinary Retention Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.68 | Urinary Retention Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.69 | Chronic Urinary Retention Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.7 | Hypoxemia Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.70 | Urinary Incontinence or Chronic Urinary Retention Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.72 | Portable Compressed Gas Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.73 | Stationary Oxygen Concentrator Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.74 | Compressed Gas Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.75 | Stationary Compressed Gas Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.76 | Portable Oxygen Concentrator Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.77 | Liquid Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.78 | Oxygen Concentrator Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.79 | Portable Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.8 | Hypoxemia Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.80 | Stationary Oxygen Therapy Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.81 | Organ Transplant History Significant to Immunosuppressive Therapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.82 | Immunosuppressive Medication HCPCS | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.83 | Medication Supporting Immunosuppressive Medication HCPCS | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.84 | Home Blood Glucose Monitor Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.85 | Insulin Medication | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.86 | Hyperglycemia or Hypoglycemia Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.87 | Hyperglycemia or Hypoglycemia Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.88 | Hyperglycemia or Hypoglycemia Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.89 | Diabetic Test Strip or Lancet Supply | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.9 | Hypoxemia Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.90 | Organ Transplant Procedure Significant to Immunosuppressive Therapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.91 | Pulmonary Hypertension Disorder SNOMEDCT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.92 | Pulmonary Hypertension Disorder ICD10CM | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.93 | Pulmonary Hypertension Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.94 | Laboratory Test for Home Glucose Monitor Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.95 | Physical Therapy Procedure SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.96 | Occupational Therapy Procedure SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.97 | Speech Language Therapy Procedure SNOMED CT | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.98 | Physical Therapy Procedure HCPCS | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.99 | Physical Therapy Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.135 | Last Menstrual Period (LMP) | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.146 | Abortion, All (ICD 10 CM) | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.149 | Abortion, All (SNOMED CT) | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.150 | Abortion, All | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.151 | Abortion, All (CPT) | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.152 | Abortion, 1st Trimester | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.153 | Abortion, 2nd Trimester | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.154 | Abortion, 2nd Trimester | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.155 | Abortion, 3rd Trimester | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.156 | Abortion, Elective | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.157 | Abortion, Elective | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.158  http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.530 | Charcot Foot | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.531 | Charcot Foot | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.533 | Cellulitis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.535 | Diabetic Hand or Diabetic Cheiroarthropathy | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.538 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.539 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.540 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.541 | Gangrene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.542 | Gangrene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.543 | Gangrene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.544 | Dupuytren's Contracture | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.545 | Dupuytren's Contracture | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.546 | Dupuytren's Contracture | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.547 | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.548 | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.549 | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.554 | Acanthosis Nigricans | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.555 | Acanthosis Nigricans | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.556 | Acanthosis Nigricans | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.557 | Eruptive Xanthomatosis | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.558 | Periodontitis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.559 | Periodontitis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.560 | Periodontitis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.561 | Amputated Limb (Not Traumatic) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.562 | Amputated Limb (Not Traumatic) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.563 | Amputated Limb (Not Traumatic) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.564 | Hypertension, Essential or Primary ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.565 | Hypertension, Essential or Primary SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.567 | Hypertension, Secondary ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.568 | Hypertension, Secondary SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.571 | Hypertension Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.579 | Cardiomyopathy | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.58 | Hypercalcemia Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.580 | NYHA Heart Failure Functional Classifications | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.581 | American Heart Association Heart Failure Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.582 | Framingham Risk Assessments | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.583 | American College of Cardiology or American Heart Association Ascvd Risk Score (acc/aha Ascvd Risk) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.584 | Atherosclerotic Cardiovascular Disease | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.586 | Gout | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.587 | Psoriatic Arthritis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.588 | Reactive Arthritis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.59 | Hypercalcemia Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.590 | Experience of Traumatic Events | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.591 | Cannabis Use | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.592 | Hearing Impairment | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.6 | Chronic Kidney Disease Type or Cause | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.60 | Hypercalcemia Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.606 | Angina | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.607 | Angina | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.608 | Angina | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.609 | Unstable Angina | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.61 | Hypocalcemia Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.610 | Unstable Angina | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.611 | Unstable Angina | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.613 | Ischemic Heart Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.614 | Ischemic Heart Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.615 | Left Ventricular Hypertrophy SCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.616 | Stroke History | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.618 | Stroke | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.619 | Transient Ischemic Attack | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.62 | Hypocalcemia Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.620 | Transient Ischemic Attack | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.621 | Transient Ischemic Attack | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.625 | Aneurysm | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.626 | Aneurysm | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.627 | Aneurysm | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.63 | Hypocalcemia Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.634 | Aortic Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.635 | Aortic Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.636 | Aortic Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.637 | Carotid Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.638 | Carotid Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.639 | Carotid Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.64 | Hyperphosphatemia Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.640 | Intracranial Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.641 | Intracranial Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.642 | Intracranial Stenosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.643 | Pulmonary Edema | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.644 | Pulmonary Edema | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.645 | Pulmonary Edema | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.646 | Osteoarthritis (Oa) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.647 | Osteoarthritis (Oa) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.648 | Osteoarthritis (Oa) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.649 | Rheumatoid Arthritis (Ra) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.65 | Hyperphosphatemia Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.650 | Rheumatoid Arthritis (Ra) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.651 | Rheumatoid Arthritis (Ra) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.652 | Infectious Arthritis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.653 | Infectious Arthritis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.654 | Infectious Arthritis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.656 | Temporomandibular Disorder Diagnosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.658 | Irritable Bowel Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.659 | Irritable Bowel Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.66 | Hyperphosphatemia Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.660 | Irritable Bowel Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.661 | Neuropathic Pain (Neuralgia) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.662 | Neuropathic Pain (Neuralgia) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.663 | Neuropathic Pain (Neuralgia) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.664 | Neuromas | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.665 | Neuromas | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.666 | Neuromas | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.667 | Phantom Pain | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.668 | Phantom Pain | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.669 | Phantom Pain | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.67 | Hematuria Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.670 | Entrapment Neuropathy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.671 | Entrapment Neuropathy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.672 | Entrapment Neuropathy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.673 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.674 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.675 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.676 | Psychotic Depression | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.677 | Psychotic Depression | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.678 | Psychotic Depression | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.679 | Post Partum Depression | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.68 | Hematuria Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.680 | Post Partum Depression | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.681 | Post Partum Depression | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.682 | Seasonal Affective Disorder | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.683 | Seasonal Affective Disorder | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.684 | Seasonal Affective Disorder | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.685 | Psychological Trauma | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.686 | Psychological Trauma | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.687 | Psychological Trauma | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.688 | Grief or Loss | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.689 | Grief or Loss | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.69 | Hematuria Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.690 | Grief or Loss | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.691 | Suicide Risk | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.692 | Suicide Risk | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.693 | Suicide Risk | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.694 | Vaping | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.695 | Vaping | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.696 | Vaping | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.697 | Tobacco Use or Exposure | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.699 | Tobacco Use or Exposure | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.70 | Metabolic Acidosis Conditions | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.701 | Binge Drinking | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.702 | Binge Drinking | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.703 | Binge Drinking | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.704 | Drug Misuse | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.705 | Drug Misuse | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.706 | Drug Misuse | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.707 | Drug Misuse | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.708 | Sensory Status | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.709 | Sensory Status | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.71 | Metabolic Acidosis Conditions ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.711 | Fall Risk | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.713 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.714 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.715 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.716 | Urinary Incontinence | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.717 | Urinary Incontinence | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.718 | Urinary Incontinence | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.719 | Urinary Urgency | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.72 | Metabolic Acidosis Conditions SCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.720 | Urinary Urgency | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.721 | Urinary Urgency | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.722 | Urinary Frequency | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.723 | Urinary Frequency | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.724 | Urinary Frequency | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.725 | Nocturia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.726 | Nocturia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.727 | Nocturia | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.728 | Pelvic Organ Prolapse | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.729 | Pelvic Organ Prolapse | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.73 | Hyperlipidemia Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.730 | Pelvic Organ Prolapse | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.731 | Erectile Dysfunction | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.732 | Erectile Dysfunction | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.733 | Erectile Dysfunction | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.734 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.735 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.736 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.737 | Recurrent Urinary Tract Infections | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.738 | Recurrent Urinary Tract Infections | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.739 | Recurrent Urinary Tract Infections | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.74 | Hyperlipidemia Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.740 | Hypertriglyceridemia | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.741 | Hypertriglyceridemia | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.742 | Hypertriglyceridemia | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.743 | Hypothyroidism | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.744 | Hypothyroidism | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.745 | Hypothyroidism | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.746 | Menopause | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.747 | Menopause | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.748 | Menopause | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.749 | Testicular Hypofunction | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.75 | Hyperlipidemia Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.750 | Testicular Hypofunction | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.751 | Testicular Hypofunction | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.752 | Primary Aldosteronism | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.753 | Primary Aldosteronism | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.754 | Primary Aldosteronism | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.755 | Restless Leg Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.756 | Restless Leg Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.757 | Restless Leg Syndrome | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.759 | Claudication | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.76 | Chronic Pain Conditions | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.760 | Claudication | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.761 | Claudication | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762 | Angioedema | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763 | Angioedema | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764 | Angioedema | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768 | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769 | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77 | Chronic Pain ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770 | Nonalcoholic Fatty Liver Disease | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771 | Thalassemia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772 | Thalassemia | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773 | Thalassemia | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78 | Chronic Pain SCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79 | Arthritis Disorders SCT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790 | Urine Protein to Creatinine Ratio (UPCR) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791 | 24 Hour Urine Volume | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792 | 24 Hour Urine Protein Excretion | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793 | Total Carbon Dioxide or Bicarbonate in blood, serum or plasma | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794 | Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serum | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795 | B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasma | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797 | N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasma | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799 | Temporomandibular Disorder Diagnosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80 | Arthritis Disorders ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800 | Temporomandibular Disorder Diagnosis | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801 | High Sensitivity Troponin | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804 | Aspartate Transaminase or Alanine Aminotransferase Ratio | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805 | Alkaline Phosphatase (Alp) in Blood, Serum or Plasma | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806 | Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasma | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807 | Triiodothyronine in serum or plasma | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808 | Fasting Blood Glucose | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809 | Random Blood Glucose Test | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81 | Arthritis Disorders | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.810 | Uric Acid (Urate) in blood, serum or plasma | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.811 | Aldosterone/Renin Ratio | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.812 | Serum Rheumatoid Factor | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.813 | Blood Ethanol Level | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.814 | Drugs of Abuse Screen in Hair | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.815 | Drugs of Abuse Screen in Urine | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.816 | Drugs of Abuse Screen in Blood | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.817 | Drugs of Abuse Screen in Tissue | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.818 | Drugs of Abuse Screen in Body Fluid | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.819 | Urea Reduction Ratio | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.82 | Preeclampsia Disorders SCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.822 | Bowel Sounds | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.823 | Uroflowmetry | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.826 | Gait Quality | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.828 | Balance Assessments | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.83 | Preeclampsia Disorders ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.836 | Sit to Stand Ability | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.84 | Preeclampsia Disorders | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.840 | Spinal Cord Compression | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.841 | Spinal Cord Compression | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.842 | Alcohol Use (Revised 2021) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.843 | Alcohol Use (Revised 2021) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.844 | Alcohol Use (Revised 2021) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.845 | Alcohol Use | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.85 | Hyperuricemia Conditions | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.86 | Hyperuricemia Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.864 | Kidney Biopsy Report | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.867 | Skin Biopsy Report | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.868 | Muscle Biopsy Report | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.869 | Gastric Tissue Biopsy Report | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.87 | Hyperuricemia Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.870 | Bone Biopsy Report | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.873 | Echocardiogram | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.88 | Vitamin D Deficiency Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.880 | Spinal or Back CT | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.881 | Chest CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.882 | Abdominal or Pelvic CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.883 | Limb CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.884 | Heart Calcium Score | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.885 | Coronary CT Angiogram | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.886 | Limb CT Angiogram | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.888 | Chest CT Angiogram | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.889 | Head and Neck CT Angiogram | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.89 | Vitamin D Deficiency Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.891 | Gastrointestinal Tract X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.892 | Gallbladder X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.893 | Kidney X Ray | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.894 | Abdomen X Ray | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.895 | Pelvis X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.896 | Hand X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.897 | Wrist X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.898 | Forearm X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.899 | Elbow X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.90 | Vitamin D Deficiency Conditions | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.900 | Upper Arm X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.901 | Shoulder X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.902 | Upper Extremity X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.903 | Foot X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.904 | Ankle X Ray | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.905 | Shin X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.906 | Knee X Ray | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.907 | Thigh X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.908 | Hip X Ray | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.909 | Lower Extremity X Ray | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.91 | Alkaline Phosphatase Deficiency Conditions SCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.910 | Abdominal MRI | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.911 | Adrenal Gland MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.912 | Kidney MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.913 | Pancreas MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.915 | Kidney MRA | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.916 | Chest Region MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.917 | Pulmonary MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.918 | Cardiac MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.92 | Alkaline Phosphatase Deficiency Conditions ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.920 | Spine MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.921 | Head and Neck MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.922 | Brain MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.923 | Pelvic Region MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.924 | Knee MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.925 | Foot MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.927 | Shoulder MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.928 | Lower Extremity MRA | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.93 | Alkaline Phosphatase Deficiency Conditions | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.930 | Spine X Ray | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.933 | Hip MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.934 | Thigh or Femur MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.935 | Ankle MRI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.936 | Lower Extremity MRI | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.937 | Forearm MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.938 | Elbow MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.939 | Wrist MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.94 | Uremic Pruritus Conditions ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.940 | Hand MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.942 | Upper Extremity MRI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.943 | Abdominal MRA | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.944 | Chest MRA | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.945 | Upper Extremity MRA | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.947 | Head and Neck MRA | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.948 | Pelvic Region MRA | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.949 | Functional MRI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.95 | Uremic Pruritus Conditions SCT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.951 | Optical Coherence Tomography | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.954 | Bathing or grooming/hygiene (ADL/IADL) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.955 | Dressing (ADL or IADL) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.956 | Toileting (ADL or IADL) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.957 | Transferring (ADL or IADL) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.958 | Walking or ambulation/locomotion (ADL/IADL) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.96 | Uremic Pruritus Conditions | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.960 | Domestic Duties or Household Tasks (ADL/IADL) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.961 | Telephone Use (ADL or IADL) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.962 | Bed Mobility (ADL or IADL) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.963 | Stair Use (ADL or IADL) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.964 | Medication Management (ADL or IADL) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.967 | Electromyography | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.968 | Electroencephalogram | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.969 | Exercise Stress Test | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.97 | Insomnia Disorders | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.976 | Sleep Duration, Device | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.977 | Steps Per Time, Device | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.978 | Physical Activity Level, Device | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.979 | Cognitive Function Clinician Interpretation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.98 | Insomnia Disorders ICD10 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.987 | Psychosis | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.99 | Insomnia Disorders SCT | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.991 | Suicidal Ideation and Behaviors | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.994 | Sleep Duration | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.996 | Pain Intensity or Severity | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.997 | Pain Quality | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.4 | Glaucoma ICD10 | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.5 | Glaucoma SNOMED | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.1 | Scleritis | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.2 | Scleritis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.3 | Scleritis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.1 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.2 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Non Diagnostic or Non CT | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.3 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Nuclear Medicine With CT | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.4 | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography CT Without Specified Body Region | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.6 | Outpatient Encounter Locations | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.7 | Outpatient Activity Codes | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.6 | Anaphylaxis, ICD10CM codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.60 | Guillain Barre Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.61 | Febrile seizure, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.62 | Encephalomyelitis and encephalitis, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.63 | Disseminated Intravascular Coagulation, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.64 | Deep Vein Thrombosis, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.65 | Bells Palsy, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.66 | Appendicitis, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.67 | Anaphylaxis, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.68 | Acute Myocardial Infarction, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.69 | Multisystem Inflammatory Syndrome, SNOMED codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.7 | Anaphylaxis, SNOMED codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.70 | Multisystem Inflammatory Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.71 | Transfusion CPT codes for exposure identification | active | 2021-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.72 | Transfusion ICD9 codes for exposure identification | active | 2021-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.73 | Transfusion ICD10PCS codes for exposure identification | active | 2021-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.74 | Transfusion CPT, ICD9, ICD10PCS codes for exposure identification | active | 2021-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75 | COVID19 vaccine ICD10PCS codes for exposure identification | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.8 | Appendicitis, SNOMED codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.9 | Appendicitis, ICD10CM codes for AE reporting | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.1 | Test Diabetes codes | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.100 | Cardiomyopathy Hypertrophic Condition | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.12 | Metabolic Syndrome LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.15 | MetabolicSyndromeCondition | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.16 | Annual Physical ICD9 CN5 | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.164 | Diabetic Retinal Screening HD CPT for Tax Pair | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.165 | Optometrist and Ophthalmologist Taxonomy HD Taxonomy | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.167 | End Stage Renal Disease (ESRD)_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.168 | End Stage Renal Disease (ESRD)_HD_ICD9 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.169 | End Stage Renal Disease (ESRD)_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.17 | Annual Physical ICD10 CN5 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.170 | End Stage Renal Disease (ESRD)_HD_HCPCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.171 | End Stage Renal Disease (ESRD)_HD_LOINC | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.172 | End Stage Renal Disease (ESRD)_HD_Clinical Condition Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.173 | Systolic Blood Pressure_HD_SNOMED | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.174 | Systolic Blood Pressure_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.175 | Systolic Blood Pressure_HD_LOINC | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.176 | Systolic Blood Pressure_HD | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.177 | Diastolic Blood Pressure_HD_SNOMED | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.178 | Diastolic Blood Pressure_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.179 | Diastolic Blood Pressure_HD_LOINC | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.18 | Annual Physical SNOMED CN5 | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.180 | Diastolic Blood Pressure_HD | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.181 | Remote Blood Pressure_HD_SNOMED | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.182 | Remote Blood Pressure_HD | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.183 | Remote Blood Pressure_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.184 | Acute Inpatient_CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.185 | Acute Inpatient_CN_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.186 | Acute Inpatient_HD_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.187 | ED Visit_CN_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.188 | ED Visit_CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.19 | Annual Physical Taxonomy CN5 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.190 | Pregnancy_HD_Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.191 | Pregnancy_CN_HD_SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.192 | Pregnancy_CN_HD_ICD10 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.193 | ED Visit_HD_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.194 | Lipid Panel_Event_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.195 | Lipid Panel_Event_HCPCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.196 | Lipid Panel_Event_LOINC | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.197 | Lipid Panel_Event_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.198 | Lipid Panel_Event_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.199 | Unknown Glucose_Event_ICD9 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.20 | Annual Physical CN5 | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.200 | Unknown Glucose_Event_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.201 | Unknown Glucose_Event_LOINC | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.202 | Unknown Glucose_Event_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.203 | Unknown Glucose_Event_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.204 | Unknown Glucose_Lab_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.205 | Bone Marrow Transplant CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.206 | Bone Marrow Transplant CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.207 | Bone Marrow Transplant_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.208 | Immunocompromising Conditions CN_HD_ICD9 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.209 | Immunocompromising Conditions CN_HD_ICD10PCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.21 | Annual Physical CPT CN5 | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.210 | Immunocompromising Conditions CN_HD_ICD10CM | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.211 | Immunocompromising Conditions_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.212 | Immunocompromising Conditions CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.213 | Cerebrospinal Fluid Leak CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.214 | Cerebrospinal Fluid Leak CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.215 | Cerebrospinal Fluid Leak_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.216 | Anatomic or Functional Asplenia CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.217 | Anatomic or Functional Asplenia CN_HD_ICD9 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.218 | Anatomic or Functional Asplenia CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.219 | Anatomic or Functional Asplenia_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.22 | Annual Physical HCPCS CN5 | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.220 | Sickle cell Anemia and HB S Disease CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.221 | Sickle cell Anemia and HB S Disease CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.222 | Sickle cell Anemia and HB S Disease_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.223 | Pneumococcal Vaccine CN_HD_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.224 | Pneumococcal Vaccine CN_HD_HCPCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.225 | Pneumococcal Vaccine CN_HD_CVX | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.226 | Pneumococcal Vaccine CN_HD_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.227 | Pneumococcal Vaccine_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.228 | Influenza Vaccine CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.229 | Influenza Vaccine CN_HD_HCPCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.23 | Annual Physical CPT for Tax Pair CN5 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.230 | Influenza Vaccine CN_HD_CVX | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.231 | Influenza Vaccine CN_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232 | Influenza Vaccine_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.233 | Cochlear Implant CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.234 | Cochlear Implant CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.235 | Cochlear Implant CN_HD_HCPCS | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.236 | Cochlear Implant CN_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.237 | Cochlear Implant_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.238 | Chemotherapy CN_HD_SNOMED | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.239 | Chemotherapy CN_HD_ICD10 | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.24 | Annual Physical ICD9 for Tax Pair CN5 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.240 | Chemotherapy CN_HD_CPT | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.241 | Chemotherapy_HD_CN_Grouping | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.244 | Fasting Blood Glucose_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.245 | Chronic Heart Failure (CHF)_ICD9 | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.246 | Chronic Heart Failure (CHF)_ICD10 | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.251 | Asthma_LOINC | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.253 | Asthma_Clinical Condition Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.254 | Pregnancy Loss_HD_SNOMED | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.255 | Pregnancy Loss_HD_ICD10 | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.257 | Pregnancy Loss_HD_Clinical Condition Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.258 | Heart Failure (CHF)_ICD9 | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.259 | Heart Failure (CHF)_ICD10 | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.260 | Heart Failure (CHF)_SNOMED | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.261 | Heart Failure (CHF)_HCPCS | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.262 | Heart Failure (CHF)_LOINC | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.263 | Heart Failure (CHF)_CPT | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.264 | Heart Failure (CHF)_RxNorm | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.265 | Heart Failure (CHF)_Clinical Condition Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.270 | Triglyceride_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.274 | Total Cholesterol_CPT | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.275 | Total Cholesterol_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.276 | LDL_SNOMED | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.280 | LDL_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.284 | HDL_LOINC | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.285 | HDL_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.286 | Colectomy_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.288 | Colectomy_ICD9 | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.29 | Hospice Exclusions Grouping | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.290 | Colectomy_Event_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.291 | CT Colonography_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.292 | CT Colonography_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.294 | CT Colonography_Event_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.295 | FIT DNA_LOINC | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.296 | FIT DNA_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.297 | FIT DNA_HCPCS | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.298 | FIT DNA_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.299 | FIT DNA Test_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.30 | Annual Physical Codes for Tax Pair CN5 | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.300 | Sigmoidoscopy_CPT | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.302 | Sigmoidoscopy_ICD9 | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.303 | Sigmoidoscopy_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.304 | Sigmoidoscopy_Event_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.305 | Colonoscopy_CPT | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.306 | Colonoscopy_HCPCS | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.307 | Colonoscopy_ICD9 | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.308 | Colonoscopy_SNOMED | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.309 | Colonoscopy_Event_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.310 | FOBT Lab_CPT | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.311 | FOBT Lab_HCPCS | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.312 | FOBT Lab_LOINC | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.313 | FOBT Lab_SNOMED | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.314 | FOBT Lab Test_Lab_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.315 | Colorectal Cancer_HD_ICD10 | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.316 | Colorectal Cancer_HD_ICD9 | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.317 | Colorectal Cancer_HD_SNOMED | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.318 | Colorectal Cancer_HD_Grouping | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.319 | Absence of Cervix Diagnosis_HD_ICD10 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.320 | Absence of Cervix Diagnosis_HD_ICD9 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.321 | Absence of Cervix Diagnosis_HD_SNOMED | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.322 | Absence of Cervix Diagnosis_HD_Grouping | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.323 | Hysterectomy With No Residual Cervix_HD_CPT | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.324 | Hysterectomy With No Residual Cervix_HD_ICD10 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.325 | Hysterectomy With No Residual Cervix_HD_ICD9 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.326 | Hysterectomy With No Residual Cervix_HD_SNOMED | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.327 | Hysterectomy With No Residual Cervix_HD_Grouping | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.328 | High Risk HPV Test_HD_CPT | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.329 | High Risk HPV Test_HD_HCPCS | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.330 | High Risk HPV Test_HD_LOINC | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.331 | High Risk HPV Test_HD_SNOMED | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.332 | High Risk HPV Test_HD_Grouping | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.333 | Cervical Cytology_HD_CPT | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.334 | Cervical Cytology_HD_HCPCS | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.335 | Cervical Cytology_HD_LOINC | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.336 | Cervical Cytology_HD_SNOMED | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.337 | Cervical Cytology_HD_Grouping | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.338 | AFib (Atrial Fibrillation)_ICD9 | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.339 | AFib (Atrial Fibrillation)_ICD10 | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.340 | AFib (Atrial Fibrillation)_SNOMED | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.341 | AFib (Atrial Fibrillation)_LOINC | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.342 | AFib (Atrial Fibrillation)_RxNORM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.343 | AFib (Atrial Fibrillation)_CPT | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.344 | AFib (Atrial Fibrillation)_Clinical Condition Grouping | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345 | COVID19 Vaccine_CPT | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346 | COVID19 Vaccine_HCPCS | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348 | COVID19 Vaccine_RxNorm | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349 | COVID19 Vaccine_CVX | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350 | COVID19 Vaccine_Event Clinical Grouping | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.351 | Coronary Artery Disease (CAD)_ICD9 | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.352 | Coronary Artery Disease (CAD)_ICD10PCS | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.353 | Coronary Artery Disease (CAD)_ICD10CM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.354 | Coronary Artery Disease (CAD)_CPT | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.355 | Coronary Artery Disease (CAD)_HCPCS | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.356 | Coronary Artery Disease (CAD)_LOINC | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.357 | Coronary Artery Disease (CAD)_SNOMED | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.358 | Coronary Artery Disease (CAD)_CUI_UMLS | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.359 | Coronary Artery Disease (CAD)_Clinical Condition Grouping | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.360 | Allergy List_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.361 | Allergy List_ICD10 | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.362 | Allergy List_Clinical Grouping Event | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.363 | Statin Use_RxNorm | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.364 | Other Revascularization_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.365 | Other Revascularization_CPT | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.366 | Other Revascularization_Grouping | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.367 | Ischemic Vascular Disease (IVD)_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.368 | Ischemic Vascular Disease (IVD)_ICD10 | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.369 | Ischemic Vascular Disease (IVD)_Grouping | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.370 | Muscular Pain and Disease_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.371 | Muscular Pain and Disease_ICD10 | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.372 | Muscular Pain and Disease_Grouping | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.373 | Cirrhosis_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.374 | Cirrhosis_ICD10 | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.375 | Cirrhosis_Grouping | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.376 | IVF_SNOMED | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.377 | IVF_HCPCS | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.378 | IVF_Grouping | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.379 | Estrogen Agonists Medications_RXNORM | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.382 | Pre_Hypertension (Pre_HTN)_Clinical Condition Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.384 | Family History Hypertension (HTN)_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.385 | Family History Hypertension (HTN)_Clinical Condition Grouping | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.386 | Obesity_Condition_UMLS | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.387 | Podiatry_Taxonomy | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.388 | Cardiology _Taxonomy | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.393 | BMI >=40_Event_Clinical Condition Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.400 | Smoker Status_Event_Clinical Condition Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.401 | First Trimester_ICD10 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.402 | First Trimester_SNOMED | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.403 | First Trimester_LOINC | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.404 | First Trimester_CPT | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.405 | First Trimester_UMLS CUI | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.406 | First Trimester_Clinical Grouping Event | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.408 | Birth Event_ICD10 | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.409 | Birth Event_SNOMED | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.413 | Birth Event_Clinical Grouping Event | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.414 | Obesity_Condition_SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.415 | Obesity_Condition_ICD10 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.416 | Obesity_Condition_ICD9 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.417 | Obesity_Clinical Grouping Condition | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.418 | Pre_Hypertension (Pre_HTN)_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.419 | Pre_Hypertension (Pre_HTN)_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.420 | Pre_Hypertension (Pre_HTN)_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.424 | BMI >=30_Event_Clinical Condition Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.427 | Obesity_Condition_LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.428 | Vitals Body Height LOINC | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.429 | Vitals Body Height SnoMed | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.430 | Vitals Body Height | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.431 | bwell_Vital_Blood Glucose_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.432 | Anxiety_Clinical Grouping Condition_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.433 | Anxiety_Clinical Grouping Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.434 | Anxiety_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.435 | Anxiety_Clinical Grouping Condition_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.436 | Anxiety_Clinical Grouping Condition | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.437 | bwell_Vital_Blood Oxygen_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.438 | bwell_Vital_Systolic Blood Pressure_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.439 | bwell_Vital_Diastolic Blood Pressure_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.440 | bwell_Vital_Heart Rate_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.441 | bwell_Vital_BMI_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.442 | bwell_Vital_Body Fat_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.443 | bwell_Vital_Body Temperature_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.444 | bwell_Vital_Body Height_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.445 | bwell_Vital_Body Weight_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.446 | bwell_Vital_Respiratory Rate_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.447 | bwell_Vital_Waist Circumference_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.448 | bwell_Vital_Blood Glucose_Clinical Grouping Lab | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.449 | bwell_Vital_Blood Oxygen_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.450 | bwell_Vital_Systolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.451 | bwell_Vital_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.452 | bwell_Vital_Heart Rate_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.453 | bwell_Vital_BMI_Clinical Grouping Event | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.454 | bwell_Vital_Body Fat_Clinical Grouping Event | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.455 | bwell_Vital_Body Temperature_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.456 | bwell_Vital_Body Height_Clinical Grouping Event | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.457 | bwell_Vital_Body Weight_Clinical Grouping Event | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.458 | bwell_Vital_Respiratory Rate_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.459 | bwell_Vital_Waist Circumference_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.460 | Pregnancy_CN_HD_LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.461 | Pregnancy_CN_HD_CPT | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.462 | Pregnancy_CN_HD_UMLS | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.463 | Second Trimester_ICD10 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.464 | Second Trimester_SNOMED | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.465 | Second Trimester_Clinical Grouping Event | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.466 | Third Trimester_SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.467 | Third Trimester_ICD10 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.468 | Third Trimester_Clinical Grouping Event | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.469 | Pregnancy Due Date_LOINC | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.470 | Second Trimester_LOINC | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.472 | OGTT_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.473 | OGTT_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.475 | OGTT_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.476 | OGTT_Grouping | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.477 | Second Trimester_CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.479 | Prostate Cancer Screening_HD_ICD9 | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.482 | Prostate Cancer Screening_HD_Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.484 | Prostate Dysplasia_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.486 | Prostate Dysplasia_Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.487 | Prostectomy_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.488 | Prostectomy_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.490 | Prostectomy_Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.494 | PSA Testing _LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.495 | PSA Testing_Grouping | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.496 | Active Pregnancy_CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.497 | Active Pregnancy_ICD10 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.498 | Active Pregnancy_LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.499 | Active Pregnancy_SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.5 | ADD/ADHD Condition | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.500 | Active Pregnancy_Clinical Grouping Event | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.501 | Abnormal PSA Testing _SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.502 | Prediabetes_Clinical Grouping Condition_ICD10 | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.503 | Prediabetes_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.504 | Prediabetes_Clinical Grouping Condition | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.505 | Third Trimester_CPT | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.506 | Third Trimester_LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.508 | bwell_Vital_Waist Circumference_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.509 | bwell_Vital_Blood Oxygen_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.510 | bwell_Vital_Body Temperature_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.511 | bwell_Vital_Diastolic Blood Pressure_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.512 | bwell_Vital_Systolic Blood Pressure_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.513 | bwell_Vital_Systolic_and_Diastolic Blood Pressure_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.514 | bwell_Vital_Systolic_and_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.515 | bwell_Vital_Heart Rate_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.516 | bwell_Vital_Respiratory Rate_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.517 | Lupus_Clinical_Condition_ICD10 | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.519 | Lupus_Clinical_Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.520 | Lupus_Clinical Condition Grouping | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.523 | UTI_Clinical_Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.524 | UTI_Clinical Condition Grouping | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.525 | Postpartum_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.526 | Postpartum_HCPCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.527 | Postpartum_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.528 | Postpartum_ICD9CM | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.529 | Postpartum_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.530 | Postpartum_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.531 | Postpartum_Clinical Grouping Event | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.532 | bwell_Vital_Head Circumference_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.533 | bwell_Vital_Head Circumference_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.534 | bwell_Vital_Head Circumference_Clinical Grouping Event | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.535 | bwell_Vital_Body Surface Area_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.536 | bwell_Vital_Body Surface Area_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.537 | bwell_Vital_Body Surface Area_Clinical Grouping Event | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.538 | bwell_Vital_Vital Signs Panel_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.539 | bwell_Vital_Vital Signs Panel_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.540 | bwell_Vital_Vital Signs Panel_Clinical Grouping Event | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.541 | bwell_Vital_Blood Pressure Panel_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.542 | bwell_Vital_Blood Pressure Panel_Clinical Grouping Event | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.543 | Depression_Clinical Grouping Condition_CPT | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.544 | Depression_Clinical Grouping Condition_HCPCS | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.545 | Depression_Clinical Grouping Condition_ICD10 | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.546 | Depression_Clinical Grouping Condition_ICD9 | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.547 | Depression_Clinical Grouping Condition_LOINC | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.548 | Depression_Clinical Grouping Condition_SNOMED | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.549 | Depression_Clinical Grouping Condition | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.550 | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.551 | MI (Myocardial Infarction)_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.552 | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.553 | MI (Myocardial Infarction)_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.554 | CABG_Clinical Grouping Condition_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.555 | CABG_Clinical Grouping Condition_HCPCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.556 | CABG_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.557 | CABG_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.558 | CABG_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.559 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.56 | Diabetic Retinal Screening HD CPT | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.560 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_HCPCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.561 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.562 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD9PCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.563 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.564 | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.565 | Essential HTN_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.566 | Essential HTN_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.567 | Essential HTN_HD_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.568 | Total and Partial Neph_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.569 | Total and Partial Neph_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.570 | Total and Partial Neph_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.571 | Total and Partial Neph_HD_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.572 | Kid Trans and Hx_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.573 | Kid Trans and Hx_HD_Clinical Grouping Condition_HCPCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.574 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10CM | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.575 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.576 | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.577 | Kid Trans and Hx_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.578 | Kid Trans and Hx_HD_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.579 | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.580 | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.581 | Systolic Less than 140_HD_Clinical Grouping Event_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.582 | Diastolic Less than 90_HD_Clinical Grouping Event_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.583 | Systolic Less than 140_HD_Clinical Grouping Event | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.584 | Diastolic Less than 90_HD_Clinical Grouping Event | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.585 | COPD_Clinical_Grouping_Condition_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.586 | COPD_Clinical_Grouping_Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.587 | COPD_Clinical_Grouping_Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.588 | COPD_Clinical Condition Grouping | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.589 | Polypharmacy_Clinical_Grouping_Condition_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.590 | Polypharmacy_Clinical_Grouping_Condition_ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.591 | Polypharmacy_Clinical_Grouping_Condition_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.592 | Polypharmacy_Clinical_Grouping_Condition_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.593 | Polypharmacy_Clinical Condition Grouping | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.595 | Thyroid Cancer_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.596 | Thyroid Cancer_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.597 | Thyroid Cancer_Grouping | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.598 | Allergy Iodine_SNOMED | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.599 | Allergy to contrast_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.600 | Allergy to contrast_ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.601 | Allergy to contrast_Grouping | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.602 | Contrast induced nephropathy_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.603 | Contrast induced nephropathy_ICD10 | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.604 | Contrast induced nephropathy_Grouping | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.605 | Systolic Blood Pressure_Compliant | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.606 | Diastolic Blood Pressure_Compliant | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.607 | Diastolic Blood Pressure_Compliant_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.608 | Systolic Blood Pressure_Compliant_CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.609 | bwell Systolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.610 | bwell Systolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.611 | bwell Diastolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.612 | bwell Diastolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.613 | bwell Combo Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.614 | bwell Combo Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.615 | bwell Systolic Blood Pressure_UI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.616 | bwell Diastolic Blood Pressure_UI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.617 | bwell Combo Blood Pressure_UI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.618 | b.well Herpes Zoster Vaccine CN_HD | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.619 | b.well Herpes Zoster Vaccine CN_HD_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.620 | b.well Herpes Zoster Vaccine CN_HD_CVX | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.621 | b.well Herpes Zoster Vaccine CN_HD_CPT | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.622 | b.well Herpes Zoster Vaccine CN_HD_2dose | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.623 | b.well Herpes Zoster Vaccine CN_HD_2dose_CPT | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.624 | b.well Herpes Zoster Vaccine CN_HD_2dose_CVX | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.625 | b.well Herpes Zoster Vaccine CN_HD_2dose_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.626 | b.well Herpes Zoster Vaccine CN_HD_Exclusions | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.627 | b.well Herpes Zoster Vaccine CN_HD_Exclusions_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.628 | b.well Adult RSV Vaccine CN_CVX | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.629 | b.well Adult RSV Vaccine CN_CPT | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.630 | b.well Adult RSV Vaccine CN_HCPCS | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.631 | b.well Adult RSV Vaccine CN_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.633 | Lp(a) Test_SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.634 | Lp(a) Test_LOINC | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.635 | LP(a) Test_ICD | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.636 | Lp(a) Test_CPT | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.637 | LP(a) Test | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.638 | b.well Adult Tetanus Vaccine CN | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.639 | BWellAdultTetanusVaccineCN_SNOMED | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.640 | b.well Adult Tetanus Vaccine CN_CPT | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.641 | b.well Adult Tetanus Vaccine CN_CVX | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.642 | b.well Adult Tetanus Vaccine CN_Exclusions_SNOMED | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.643 | b.well Adult Tetanus Vaccine CN_Exclusions | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.644 | BWellAdultTetanusVaccineCN_RxNorm | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.645 | Pneumococcal Vaccine HD_CN_ Allergy | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.646 | bwell COVID Vaccine CN_Allergy | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.647 | bwell Covid Vaccine CN_Allergy_SNOMED | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.648 | bwell COVID Vaccine CN_Met | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.9 | Metabolic Syndrome ICD10 | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.91 | Cardiomyopathy Dilated ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.92 | Cardiomyopathy Dilated ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.93 | Cardiomyopathy Dilated SNOMED | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.94 | Cardiomyopathy Dilated Condition | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.95 | Cardiomyopathy Dilated LOINC | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.96 | Cardiomyopathy Hypertrophic ICD9 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.97 | Cardiomyopathy Hypertrophic ICD10 | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.98 | Cardiomyopathy Hypertrophic SNOMED | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.99 | Cardiomyopathy Hypertrophic LOINC | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.12 | SNOMEDFindingValuesQualifierValue | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.13 | SNOMED Organism from LOINC Answer List | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18 | Medication Prescribable Brand Name | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.2 | SNOMED Organisms | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22 | Medicinal Ingredients RXNORM | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.1 | Mental Status Observation | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.10 | Other Unknown Nulls | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.11 | Sexual Orientation Including nulls and Data Absent Reason | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.12 | Pregnancy Status Observation | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.2 | No Healthcare Agent Included Reason | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.3 | Sex | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.4 | Asked Declined Data Absent Reason | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.5 | Act Encounter Codes | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.6 | Completed or Nullified Act Status | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.7 | Data Absent Reason Types of Unknown | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.8 | Medication Adherence | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.2 | Sickle Cell Disease | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.4 | Depression | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.1 | Food Insecurity Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.100 | Intimate Partner Violence Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.101 | Less Than High School Education Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.102 | Less Than High School Education Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.103 | Less Than High School Education Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.106 | Transportation Insecurity Interventions SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.107 | Financial Insecurity Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.108 | Financial Insecurity Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.109 | Financial Insecurity Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.11 | Food Insecurity Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.110 | Medical Cost Burden Goals SNOMED CT | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.111 | Health Insurance Coverage Status Goals SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.112 | Health Literacy Diagnoses SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.113 | Health Literacy Diagnoses ICD10CM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.114 | Health Literacy Goals SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.115 | Health Literacy Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.116 | Health Literacy Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.117 | Health Literacy Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.118 | Health Literacy Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.119 | Health Literacy Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.120 | Medical Cost Burden Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.121 | Health Insurance Coverage Status Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.122 | Medical Cost Burden Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.123 | Medical Cost Burden Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.124 | Health Insurance Coverage Status Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.125 | Health Insurance Coverage Status Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.126 | Social Determinants of Health Screening Assessments | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.127 | Food Insecurity Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.128 | Transportation Insecurity Screening Assessments | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.129 | Homelessness Screening Assessments | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.13 | Homelessness Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.130 | Housing Instability Screening Assessments | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.131 | Inadequate Housing Screening Assessments | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.132 | Less Than High School Education Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.133 | Unemployment Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.134 | Veteran Status Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.135 | Social Connection Screening Assessments | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.136 | Stress Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.137 | Cognitive disorder Diagnosis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.138 | Financial Insecurity Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.139 | Material Hardship Screening Assessments | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.14 | Homelessness Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.140 | Intimate Partner Violence Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.141 | Health Literacy Screening Assessments | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.142 | Medical Cost Burden Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.143 | Health Insurance Coverage Status Screening Assessments | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.144 | Elder Abuse Screening Assessments | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.145 | Less Than High School Education Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.146 | Financial Insecurity Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.147 | Health Insurance Coverage Status Diagnoses ICD10CM | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.148 | Health Insurance Coverage Status Diagnoses | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.149 | Health Insurance Coverage Status Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.15 | Food Insecurity Interventions CPT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.150 | Material Hardship Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.151 | Medical Cost Burden Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.152 | Medical Cost Burden Diagnoses SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.153 | Medical Cost Burden Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.154 | Medical Cost Burden Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.157 | Transportation Insecurity Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.158 | Homelessness Goals SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.159 | Homelessness Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.16 | Food Insecurity Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.160 | Housing Instability Goals SNOMED CT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.161 | Housing Instability Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.162 | Transportation Insecurity Goals SNOMED CT | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.163 | Transportation Insecurity Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.164 | Veteran Status Interventions SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.167 | Inadequate Housing Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.168 | Material Hardship Screening Assessments Questions | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.169 | Stress Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.17 | Food Insecurity Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.170 | Transportation Insecurity Screening Assessments Questions | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.171 | Unemployment Screening Assessments Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.172 | Veteran Status Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.173 | Financial Insecurity Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.174 | Food Insecurity Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.175 | Health Literacy Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.176 | Homelessness Screening Assessments Answers | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.177 | Housing Instability Screening Assessments Answers | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.178 | Inadequate Housing Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.179 | Less Than High School Education Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.18 | Homelessness Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.180 | Material Hardship Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.181 | Stress Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.182 | Transportation Insecurity Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.183 | Unemployment Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.184 | Veteran Status Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.185 | Health Insurance Coverage Status Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.186 | Health Insurance Coverage Status Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.187 | Medical Cost Burden Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.188 | Medical Cost Burden Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.189 | Elder Abuse Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.19 | Homelessness Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.190 | Elder Abuse Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.191 | Elder Abuse Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.192 | Veteran Status Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.193 | Financial Insecurity Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.194 | Food Insecurity Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.195 | Health Literacy Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.196 | Homelessness Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.197 | Housing Instability Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.198 | Intimate Partner Violence Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.199 | Less Than High School Education Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.20 | Homelessness Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.200 | Material Hardship Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.201 | Medical Cost Burden Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.202 | Social Connection Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.203 | Stress Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.204 | Transportation Insecurity Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.205 | Unemployment Screening Assessments And Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.206 | Social Determinants of Health Screening Assessments And Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.207 | Social Determinants of Health Screening Assessments Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.208 | Social Determinants of Health Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.209 | Intimate Partner Violence Screening Assessments Answers | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.21 | Homelessness Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.210 | Social Connection Screening Assessments Answers | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.211 | Intimate Partner Violence Screening Assessments Questions | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.212 | Social Connection Screening Assessments Questions | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.213 | Health Insurance Coverage Status Diagnoses SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.214 | Veteran Status Goals | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.215 | Veteran Status Goals SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.217 | Digital Literacy Diagnoses SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.218 | Digital Literacy Diagnoses ICD10CM | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.219 | Digital Literacy Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.22 | Housing Instability Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.220 | Digital Literacy Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.224 | Digital Literacy Diagnoses | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.225 | Digital Literacy Goals | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.226 | Digital Literacy Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.227 | Digital Literacy Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.229 | Digital Access Diagnoses SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.23 | Housing Instability Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.230 | Digital Access Diagnoses ICD10CM | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.231 | Digital Access Diagnoses | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.232 | Digital Access Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.233 | Digital Access Goals | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.234 | Digital Access Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.235 | Digital Access Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.236 | Digital Access Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.237 | Digital Access Screening Assessments | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.238 | Digital Access Screening Assessments Questions | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.239 | Digital Access Screening Assessments Answers | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.24 | Housing Instability Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.240 | Digital Access Screening Assessments And Questions | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.241 | Utility Insecurity Diagnoses SNOMED CT | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.242 | Utility Insecurity Diagnoses ICD10CM | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.243 | Utility Insecurity Diagnoses | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.244 | Utility Insecurity Goals SNOMED CT | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.245 | Utility Insecurity Goals | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.246 | Utility Insecurity Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.247 | Utility Insecurity Procedures | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.248 | Utility Insecurity Screening Assessments | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.249 | Utility Insecurity Screening Assessments Questions | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.25 | Transportation Insecurity Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.250 | Utility Insecurity Screening Assessments Answers | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.251 | Utility Insecurity Screening Assessments And Questions | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.252 | Utility Insecurity Service Requests | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.253 | Social Determinants of Health General Interventions HCPCS | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.254 | Incarceration Status Diagnoses ICD10CM | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.255 | Incarceration Status Diagnoses SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.256 | Incarceration Status Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.257 | Incarceration Status Goals | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.258 | Incarceration Status Diagnoses | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.259 | Incarceration Status Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.26 | Transportation Insecurity Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.260 | Incarceration Status Procedures | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261 | Incarceration Status Service Requests | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262 | Language Access Diagnoses | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263 | Language Access Diagnoses ICD10CM | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264 | Language Access Diagnoses SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265 | Language Access Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266 | Language Access Goals | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267 | Language Access Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268 | Language Access Procedures | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269 | Language Access Service Requests | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27 | Transportation Insecurity Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270 | Language Access Screening Assessments | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271 | Language Access Screening Assessments Answers | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272 | Language Access Screening Assessments Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273 | Language Access Screening Assessments And Questions | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28 | Transportation Insecurity Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29 | Financial Insecurity Goals SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3 | Food Insecurity Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30 | Financial Insecurity Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31 | Financial Insecurity Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32 | Financial Insecurity Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33 | Material Hardship Diagnoses ICD10CM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34 | Material Hardship Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35 | Material Hardship Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36 | Material Hardship Goals SNOMED CT | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37 | Material Hardship Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38 | Material Hardship Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39 | Material Hardship Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4 | Food Insecurity Goals SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40 | Unemployment Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41 | Unemployment Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42 | Unemployment Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43 | Housing Instability Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44 | Housing Instability Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45 | Housing Instability Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46 | Inadequate Housing Diagnoses SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47 | Inadequate Housing Diagnoses ICD10CM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48 | Inadequate Housing Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49 | Inadequate Housing Goals SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5 | Social Determinants of Health General Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50 | Inadequate Housing Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51 | Inadequate Housing Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52 | Inadequate Housing Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53 | Inadequate Housing Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54 | Less Than High School Education Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55 | Less Than High School Education Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56 | Less Than High School Education Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57 | Less Than High School Education Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58 | Unemployment Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59 | Unemployment Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6 | Food Insecurity Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60 | Unemployment Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61 | Elder Abuse Diagnoses ICD10CM | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62 | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63 | Elder Abuse Diagnoses | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64 | Elder Abuse Goals SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65 | Elder Abuse Goals | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66 | Elder Abuse Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67 | Elder Abuse Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68 | Elder Abuse Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69 | Unemployment Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7 | Food Insecurity Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70 | Unemployment Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71 | Social Determinants of Health Goals | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72 | Stress Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73 | Stress Interventions SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74 | Stress Diagnoses ICD10CM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75 | Stress Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76 | Veteran Status Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77 | Veteran Status Diagnoses ICD10CM | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78 | Veteran Status Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79 | Social Connection Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8 | Social Determinants of Health General Interventions CPT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80 | Social Connection Diagnoses ICD10CM | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81 | Social Connection Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82 | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83 | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84 | Intimate Partner Violence Diagnoses | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85 | Stress Goals SNOMED CT | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86 | Stress Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87 | Stress Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88 | Social Connection Goals SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89 | Social Connection Goals | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9 | Food Insecurity Interventions HCPCS | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90 | Veteran Status Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91 | Veteran Status Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92 | Stress Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93 | Social Connection Interventions SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94 | Social Connection Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95 | Social Connection Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96 | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97 | Intimate Partner Violence Procedures | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98 | Intimate Partner Violence Service Requests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99 | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105 | Mechanical Ventilation Procedures | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106 | Mechanical Ventilation | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107 | Mechanical Ventilation | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109 | aPTT Tests | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 | Opioid Antagonist | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12 | High Risk Diagnosis for AKI | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120 | Opioids | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124 | Immune Modulators | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130 | Suicide Attempt | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134 | Central Nervous System Depressants | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136 | Leukemia or Lymphoma | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137 | Liver Disease Moderate to Severe | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138 | COVID19 | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139 | COVID 19 | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14 | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140 | COVID 19 | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162 | Obesity | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163 | Antidepressants | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164 | Antihypertensives | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165 | Delirium | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166 | Dementia | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167 | Psychosis | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168 | Delirium or Dementia and Other Psychoses | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169 | Depression | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170 | Diuretics | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171 | Epilepsy | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172 | Neurologic Movement Disorders | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173 | Neurologic Disorders, Other | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174 | Neurologic Movement and Related Disorders | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175 | Peripheral Neuropathy | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176 | Stroke | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177 | Abnormal Weight Loss and Malnutrition | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178 | Intubation | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179 | Intubation | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180 | Tracheostomy Procedures | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181 | Tracheostomy Procedures | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185 | Spinal Surgery | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 | Routes of Administration for Opioid Antagonists | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19 | High Risk Procedures for AKI | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197 | Hospital Based Dialysis Services | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198 | Hospital Based Dialysis Services | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199 | Hospital Based Dialysis Services | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200 | Nephrectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201 | Thrombotic Thrombocytopenic Purpura | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204 | VTE Prophylaxis | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205 | Moderate Injuries | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206 | General and Neuraxial Anesthesia | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207 | General and Neuraxial Anesthesia | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208 | General and Neuraxial Anesthesia | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209 | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21 | Creatinine Mass Per Volume | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210 | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211 | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213 | Non Invasive Oxygen Therapy | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214 | Non Invasive Oxygen Therapy Devices | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216 | Procedural Hospital Locations | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217 | ASA physical status class | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218 | Blood urea nitrogen lab test | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219 | Hemoglobin lab test | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22 | Anticoagulants for All Indications | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220 | Smoking status | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221 | Albumin lab test | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222 | Leukocyte count lab test | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223 | Bilirubin lab test | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224 | Aspartate transaminase lab test | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226 | Cardiac Arrest | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23 | Coagulation Disorders | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230 | PO Antibacterials | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231 | Injectable Antifungals | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238 | Neuromuscular Disorder | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239 | Neuromuscular Disorder | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24 | Malignant Bone Disease | active | 2022-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240 | Degenerative Neurological Disorder | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241 | Degenerative Neurological Disorder | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242 | Heart and Lung Transplants | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243 | Heart and Lung Transplants | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245 | Lung Resections and Excisions | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246 | Lung Resections and Excisions | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247 | Chest Wall Procedures | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248 | Chest Wall Procedures | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249 | Maxillary Procedures | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250 | Maxillary Procedures | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251 | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252 | Anesthesia Requiring Monitored Care | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253 | Anesthesia Requiring Monitored Care | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255 | Anesthesia Requiring Monitored Care | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256 | Osteoporosis | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260 | Rivaroxaban Anticoagulant | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262 | Fondaparinux Anticoagulant | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263 | Dalteparin Anticoagulant | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264 | Heparin | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268 | Enoxaparin Anticoagulant | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271 | Undetectable Lab Result Value | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272 | Undetectable Lab Result Value | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274 | Dietary Recommendations | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275 | Bariatric Procedures | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 | Telemedicine Services | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277 | Prostate Cancer Treatment | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28 | Traumatic Avulsion of Kidney | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29 | Rapidly Progressive Nephritic Syndrome | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301 | LDL Cholesterol | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33 | Obstetrics and VTE Obstetrics | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 | Glucose Lab Test Mass Per Volume | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349 | Tuberculosis for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350 | Tuberculosis for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 | Tuberculosis for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 | Androgen Deprivation Therapy for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 | Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 | Bladder Cancer for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 | Chemotherapy Agents for Advanced Cancer | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356 | Cystectomy for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357 | Cystectomy for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 | Cystectomy for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 | DEXA Bone Density for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360 | Hospital Services for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361 | Immunocompromised Conditions | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362 | Immunocompromised Conditions | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 | Immunocompromised Conditions | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 | Immunosuppressive Drugs for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366 | Morbid Obesity | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367 | Morbid Obesity | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368 | Morbid Obesity | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370 | Urinary Retention | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371 | Urinary Retention | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372 | Urinary Retention | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374 | Face to Face Interaction | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375 | Face to Face Interaction | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376 | HIV Viral Load Tests | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377 | HIV Viral Load Tests | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389 | Syphilis Tests | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4 | Nephrectomy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79 | Acute Brain or Spinal Injury or Hemorrhage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8 | Large Body Surface Area (BSA) Burns | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80 | Pulmonary Arterial Thrombectomy | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81 | Extracorporeal Membrane Oxygenation | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85 | Elective Inpatient Encounter | active | 2023-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86 | Intubation | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88 | Acute Respiratory Failure | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89 | Tracheostomy Diagnoses | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90 | Tracheostomy Procedures | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91 | Neuromuscular Disorder | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92 | Degenerative Neurological Disorder | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94 | Oxygen Partial Pressure in Arterial Blood | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95 | Carbon Dioxide Partial Pressure in Arterial Blood | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96 | Arterial Blood pH | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2 | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3 | Psychological or Neuropsychological Testing | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10 | Tricuspid Valve Regurgitation | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12 | Hypertension | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2 | Valvular Heart Disease | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22 | Acute Kidney Injury | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23 | Anemia | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24 | Cardiac Arrhythmias | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25 | Attention Deficit and Hyperactivity Disorder | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26 | Cerebrovascular Disease | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27 | Seizure Disorder | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28 | Proteinuria | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29 | Thyroid Hormone Disorder | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30 | Thromboembolic Disease | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31 | Parkinson's Disease and Parkinsonism | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32 | Upper GI Diseases | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33 | Failure to Thrive | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34 | Osteoporosis | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35 | Mood Disorders | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36 | Dyslipidemia | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37 | Heart Failure | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38 | Coronary Artery Disease | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39 | Chronic Kidney Disease | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40 | Chronic Obstructive Pulmonary Disease | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41 | Diabetes Mellitus | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1 | EventTiming-TimingEvent | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2 | EventTiming-EventTiming | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1 | Gonorrhea Screening | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2 | Abnormal Weight Loss | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2 | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3 | Prescribable brand and generic insulins and analogues | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4 | eGFR Using 2021 Race Free Formulas | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5 | Fructosamine in Serum or Plasma | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6 | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7 | Creatinine in serum/plasma | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9 | IgE Agonists, prescribable | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10 | Estrogen Receptor Testing for Orserdu | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100 | MMR Proficient | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101 | Systemic Cancer Directed Therapy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102 | Face To Face Interaction | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104 | Erdafitinib | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107 | Chemotherapy Encounter | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108 | Urothelial Cancers ICD9 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109 | Urothelial Cancer ICD10 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11 | Estrogen Receptor Test for Orserdu | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110 | Urothelial Cancers | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111 | Prior Therapies for Erdafitinib | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112 | Urothelial Cancer Histologies | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113 | Malignant Tumor Behavior | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114 | Localized Bladder Cancer Stage SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116 | Localized Bladder Cancer Staging | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117 | Advanced Bladder Cancer Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118 | Localized Bladder Cancer T Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119 | Localized Bladder Cancer T Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12 | Negative | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120 | Localized Bladder Cancer N Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121 | Localized Bladder Cancer M Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122 | Advanced Bladder Cancer M Stage | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124 | Locoregional Urothelial Cancer ICD9 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125 | Locoregional Urothelial Cancer ICD10 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126 | Locoregional Urothelial Cancer SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127 | Locoregional Urothelial Cancer | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128 | FGFR3 Gene | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129 | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13 | HER2 Negative | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130 | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131 | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133 | FGFR3 Gene Interpretation Positive | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134 | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135 | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137 | FGFR3 Gene Interpretation Negative | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138 | FGFR3 Molecular Variants | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139 | Tumor Behavior | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14 | Endocrine Therapy | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140 | Physcological Support for Cancer | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141 | Referral For Pain From Cancer | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142 | Cancer Pain Education | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143 | Telehealth Encounters | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144 | Pain Assessment Score | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146 | Telehealth Encounters SNOMEDCT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147 | Telehealth Encounters CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148 | Telehealth Encounters HCPCS | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149 | Telehealth Encounters All | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15 | All Metastatic Sites | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150 | Chemo Admin SNOMEDCT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151 | Chemo Admin CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152 | Chemo Admin HCPCS | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153 | Chemotherapy Administration All | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154 | Radiation Treatment CPT | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155 | Radiation Treatment HCPCS | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156 | Radiation Treatment SNOMEDCT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157 | Radiation Treatment All | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158 | Bipolar Diagnosis Codes | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159 | Telephone Visits SNOMED | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16 | All Metastatic Sites | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160 | Telephone Visit CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161 | Telephone Visits All | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162 | Adolescent depression screening assessment | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163 | Adult depression screening assessment LOINC | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165 | Referral for Depression Adult | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166 | Referrals for Adolescent Depression | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167 | Follow Ups for Adolescent Depression | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168 | FollowUps for Adult Depression | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169 | Depression Screen Declined for Medical Reason | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17 | Metastatic Breast Cancer | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170 | Physical Therapy Evaluations SNOMEDCT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171 | Physical Therapy Evaluation CPT | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172 | Physical Therapies Evaluations | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173 | Non Opioid Analgesics | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174 | Adjuvant Analgesics | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176 | Lung Cancer ICD9 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177 | Lung Cancer ICD10 | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178 | Lung Cancer | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179 | Prior Therapies for Osimertinib | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18 | Stage IA | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181 | Plan of Care for Pain | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182 | All Antineoplastic Agents | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183 | Locally Advanced NSCLC Stage Group | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185 | Localized NSCLC Stage Group SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186 | Radiation Treatment Management | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187 | Plan of Care | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188 | Documentation of Plan of Care | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189 | Pain Present | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19 | Stage IB | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190 | Localized NSCLC Stage Group NCIM | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192 | Localized NSCLC Stage Group | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193 | Advanced NSCLC Stage Group | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194 | NSCLC M Stage (metastatic) | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195 | NSCLC T Stage | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196 | NSCLC N Stage | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197 | SCLC and rarer lung cancer histology | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198 | EGFR Gene | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199 | EGFR Gene Interpretation Positive SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20 | Stage IIA | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200 | EGFR Gene Interpretation Positive LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201 | EGFR Gene Interpretation Positive | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202 | EGFR Osimertinib Molecular Variants | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203 | EGFR Generic Molecular Variant NCIM | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204 | EGFR Generic Molecular Variant SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205 | EGFR Generic Molecular Variant LOINC | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206 | EGFR Molecular Variants Osimertinib PM | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207 | Osimertinib | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208 | Pemetrexed | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209 | Radiation Treatment Management SNOMEDCT | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21 | Stage IIB | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210 | Radiation Treatment Management Codes | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211 | Radiation Treatment Delivery CPT | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212 | 77427 Management Code | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213 | Radiation Treatment Delivery HCPCS | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214 | Radiation Treatment Delivery NCIM | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215 | Radiation Treatment Delivery SNOMED | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216 | Radiation Treatment Delivery | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217 | MET Gene Test | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219 | Tepotinib | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22 | Stage IIIA | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220 | MET Positive gene interpretation | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227 | MET Exon 14 skipping molecular variant | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23 | Stage IIIB | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230 | All Cancer Directed therapies | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231 | EGFR Amivantamab Molecular Variants | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232 | EGFR Molecular Variants Amivantamab PM | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233 | test43 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234 | ROS1 Molecular Variants Repotrectinib PM | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235 | ROS1 Repotrectinib Molecular Variants | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236 | ROS1 Negative (geneinterpretation) SNOMEDCT | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237 | ROS1 Negative (geneinterpretation) NCI | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238 | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239 | ROS1 Positive (geneinterpretation) | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24 | Stage IIIC | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240 | ROS1 results (HGNC) | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241 | ROS1 Gene Rearrangement | active | 2024-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242 | RET Test (HGNC) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243 | RET Positive (Genei interpretation ) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244 | RET Gene Rearrangement | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245 | RET Negative (geneinterpretaion) SNOMED | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246 | RET Negative (geneinterpretaion) NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247 | RET Negative (geneinterpretaion) SNOMEDCT,NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248 | RET Fusion Molecular Variants | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249 | pralsetinib | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25 | ESR1 Gene Test | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250 | Repotrectinib Value set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251 | Amivantamab | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252 | Alectinib Drug | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253 | Gemcitabine Drug Value set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254 | vinorelbine Drug | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255 | NSCLC_Tumor_resection SNOMEDCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256 | NSCLC_Tumor_resection CPT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257 | NSCLC_Tumor_resection SNOMEDCT CPT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258 | ALK results (HGNC) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259 | ALK Positive (geneinterpretation) SNOMED | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26 | ESR1 Genetic Mutation | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260 | ALK Positive (geneinterpretation) NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261 | ALK Positive (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262 | ALK Negative (geneinterpretation) SNOMEDCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263 | ALK Negative (geneinterpretation) NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264 | ALK Negative (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265 | Locoregional Sites | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266 | NSCLC N2 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267 | NSCLC N1 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268 | NSCLC N0 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269 | NSCLC T3_T4 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27 | Genetic Test Finding | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270 | NSCLC T2 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271 | NSCLC T1 Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272 | Locally_Advanced_Metastatic_NSCLC Stage Group | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273 | Localized_Inclusion_NSCLC Stage Group | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274 | Localized_Exclusion_NSCLC Stage Group | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275 | tarlatamab dlle | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276 | Extensive SCLC Stage Group SNOMEDCT | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277 | Extensive SCLC Stage Group NCIM | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278 | Extensive SCLC Stage Group | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279 | Localized SCLC Stage Group | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28 | Her2 Negative | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280 | SCLC M Stage (metastatic) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281 | SCLC T Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282 | SCLC N Stage | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283 | SCLC histology (to include those patients) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284 | Binimetinib | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285 | Encorafenib | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286 | Encorafenib PM Molecular variant | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288 | BRAF Positive (geneinterpretation) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289 | BRAF test (HGNC) | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29 | HER2 Positive | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292 | Prior therapy for Amivantamab | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293 | ENHERTU Drug | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294 | Metastatic_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295 | Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296 | Localized_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297 | Solid cancer M Stage (metastatic) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298 | Solid Cancer T Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299 | Solid Cancer N Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30 | HER2 Positive | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302 | HER2_IHC_Positive | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303 | HER2 Negative (geneinterpretation/Labtestvalue) SNOMED | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304 | HER2 Negative (geneinterpretation/Labtestvalue) LOINC | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305 | HER2 Negative (geneinterpretation/Labtestvalue) NCI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307 | HER2 Negative (geneinterpretation/Labtestvalue) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308 | Solid Cancer Diagnosis ICD 9 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309 | Solid Cancer Diagnosis SNOMED CT | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31 | HER2 Positive | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310 | Solid Cancer Diagnosis | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311 | Localized_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313 | Localized_Solid_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314 | Locally_Advanced_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315 | Locally_Advanced_Solid_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316 | Metastatic_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317 | Metastatic_Solid_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318 | Solid Cancer T Stage LOINC | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319 | Solid Cancer T Stage NCI | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32 | HER2 Positive | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320 | Solid Cancer T Stage codes | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321 | Prior_Systemic_therapy_Enhertu | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322 | RET test_Solid_cancer (HGNC) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323 | RET Positive_Solid_Cancer (geneinterpretation) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324 | RET Negative_Solid_Cancer (geneinterpretation) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325 | RET fusion Molecular Variants_Solid_Cancer | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326 | Prior_systemic_therapy_Retevmo | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327 | Selpercatinib (Retevmo) Drug | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328 | Breast Cancer Diagnosis ICD9 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329 | Breast Cancer Diagnosis ICD10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33 | Metastatic Breast Cancer | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330 | Breast Cancer Diagnosis | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331 | Metastatic_Breast_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332 | Locally_Advanced_Breast_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333 | Localized_Breast_Cancer_Stage Group | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334 | Breast cancer M Stage (metastatic) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335 | Breast Cancer T Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336 | Breast Cancer N Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337 | Metastatic Sites All Breast SNOMEDCT | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338 | Metastatic Sites All Breast ICD9 | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339 | Metastatic Sites All Breast ICD10 | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340 | Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341 | Aromatase_Inhibitor therapy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342 | Capivasertib_therapy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343 | Fulvestrant_therapy | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344 | PTEN_gene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345 | PTEN_geneinterpretation | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346 | PIK3CA_gene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347 | PI3KCA_geneinterpretation | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348 | AKTI_gene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349 | AKTI_geneinterpretation | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35 | All Metastatic Sites | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350 | Progesterone_receptor_gene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351 | Progesterone_receptor_geneinterpretation | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352 | Estrogen_receptor_gene | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353 | Estrogen_receptor_geneinterpretation | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354 | Progesterone_receptor_labtest | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355 | Progesterone_receptor_labinterpretation | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356 | Estrogen_receptor_labtest | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357 | Estrogen_receptor_labinterpretation | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358 | NSCLC M0 Stage | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359 | HER2_IHC_test_Gene | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36 | All Metastatic Sites | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360 | HER2_IHC_test_Lab | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361 | HER2_Fish_test | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362 | HER2_IHC_Negative | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363 | Trodelvy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364 | Chemotherapy_breast_cancer | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365 | Cyclin_dependent_kinase | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366 | Taxane_Trodelvy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367 | Endocrine_therapy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368 | HER2_Fish_test_Negative | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369 | HER2_IHC_Equivocal | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37 | Locoregional Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370 | HER2 Positive_PM_results | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371 | HER2 test_Lab | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372 | HER2 test_gene | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374 | Thyroid Cancer Diagnosis | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375 | Metastatic_Thyroid_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376 | RET mutation_Molecular Variants | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377 | RET Gene mutation | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378 | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379 | Thyroid cancer M1_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38 | Locoregional Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380 | Thyroid_cancer_M0_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381 | Thyroid_cancer_T_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382 | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383 | Thyroid_cancer_T4_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384 | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385 | Thyroid_cancer_N_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386 | Medullary_thyroid_histology | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387 | RET test_Thyroid_cancer (HGNC) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388 | RET Positive | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389 | NSCLC N3 Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39 | Locoregional Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390 | CRC Cancer Diagnosis ICD9 | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391 | CRC Cancer Diagnosis ICD10 | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392 | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393 | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394 | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395 | CRC cancer M Stage (metastatic) | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396 | CRC Cancer T Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397 | CRC Cancer N Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398 | KRAS_gene | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399 | KRAS_negative | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40 | Locoregional Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400 | Fluoropyrimidine_CRC | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401 | Oxaliplatin | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402 | Irinotecan_based_therapy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403 | anti_VEGF_therapy_CRC | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404 | anti_EGFR_therapy_CRC | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405 | fruquitinib | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406 | Locally_Advanced_CRC_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407 | Localized_CRC_Stage Group | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408 | CRC cancer M0_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409 | CRC_Cancer_T1_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41 | All Metastatic Sites ICD910 | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410 | CRC_Cancer_T2_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411 | CRC_Cancer_T3_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412 | CRC_Cancer_T4_Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413 | CRC Cancer N1 Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414 | CRC Cancer N2 Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415 | CRC Cancer N2b Stage | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416 | KRAS_G12C_MV | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417 | KRAS_G12C_PM | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418 | KRAS_positive | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419 | Adagrasib | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42 | Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420 | cetuximab_therapy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421 | Tamoxifen_therapy | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423 | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425 | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426 | Endometrial Cancer Diagnosis | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428 | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429 | Localized_Endometerial_Stage Group NCIM | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43 | Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431 | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432 | Endometrial cancer M Stage (metastatic) | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433 | Endometrial_M0_Stage | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436 | Prior_therapy_Endometrial | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437 | Paclitaxel_therapy | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44 | Breast Cancer | active | 2023-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441 | Carboplatin_therapy | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442 | Durvalumab_therapy | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444 | MMR_Gene_Lab_LOINC | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447 | MMR_Gene_HGNC | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449 | Endometrial_ Cancer N Stage | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45 | Endometrial Cancer ICD9 | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451 | Endometrial_N0_Stage | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453 | < http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.321 | Hip Replacement Surgery | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.323 | Hip Fracture Surgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.325 | Hip Fracture Surgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.328 | Venous Thromboembolism | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.33 | Galactosemia | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.330 | Venous Thromboembolism | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.331 | Urological Surgery | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.333 | Urological Surgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.335 | Obstetrical or Pregnancy Related Conditions | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.337 | Obstetrical or Pregnancy Related Conditions | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.338 | Obstetrics VTE | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.340 | Obstetrics VTE | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.344 | Intracranial Neurosurgery | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.346 | Intracranial Neurosurgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.348 | General or Neuraxial Anesthesia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.35 | Galactosemia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.361 | General Surgery | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.365 | General Surgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.367 | Cesarean Birth | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.369 | Cesarean Birth | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.37 | Parenteral Nutrition | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.38 | Parenteral Nutrition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.384 | Medical Induction of Labor | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.393 | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.395 | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2025-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.400 | Low Risk | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.401 | Delivery Procedures | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.418 | Classical Cesarean Birth | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.419 | Classical Cesarean Birth | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.421 | Classical Cesarean Birth | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.422 | Myomectomy | active | 2024-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.423 | Statin Allergen | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424 | Nonelective Inpatient Encounter | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473 | Medical Reason For Not Providing Treatment | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.75 | Neonatal Intensive Care Unit | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.76 | Single Live born Newborn | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.78 | Galactosemia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.79 | Parenteral Nutrition | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87 | Discharge To Acute Care Facility | active | 2021-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93 | Patient Refusal | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.1047 | Skin Melanoma pT1 | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100 | Injectable Fluorouracil | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.101 | Trastuzumab and Biosimilars | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.102 | Breast Cancer | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.103 | HER2 Presence in Tissue | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.104 | Depression Screening for Adult | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.105 | Long Acting Opioids | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.106 | High Fiber Supplement or Diet Education | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.107 | Standardized Assessment Tools for Dyspnea | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.108 | Nausea or Vomiting Assessment | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.109 | Pancreatic Cancer | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.110 | Pancreatic Cancer | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.111 | Audio Visual Telehealth Encounter | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.112 | Telephone Encounter | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.113 | Telehealth Emergency Department or Initial Inpatient | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.114 | Karnofsky Performance Status | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.115 | Referral to Hospice Care | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.116 | Referral to Palliative Care | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.117 | Assessment Scale for Dyspnea | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.118 | Nausea or Vomiting Assessment | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.119 | Enrollment in Hospice Care | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.120 | Palliative Care | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.121 | Advance Directive Including Durable Power of Attorney or Instructional | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.122 | Carmustine Injectable | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.123 | Dacarbazine Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.124 | Streptozocin Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.126 | Alemtuzumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.127 | Azacitidine Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.128 | Bendamustine Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.129 | Busulfan Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.130 | Temozolomide Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.131 | Thiotepa Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132 | Oxaliplatin Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.133 | Romidepsin Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.134 | Trabectedin Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135 | Dolasetron Oral | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.136 | Dolasetron Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.137 | Granisetron Oral | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138 | Granisetron Transdermal | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.139 | Granisetron Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.140 | Ondansetron Oral | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.141 | Ondansetron Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.142 | Ifosfamide Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.143 | Arsenic Trioxide Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144 | Netupitant Palonosetron Oral | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145 | Fosnetupitant Palonosetron Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146 | Aprepitant Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147 | Rolapitant Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.148 | Dexamethasone Oral | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.149 | Dexamethasone Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.150 | Dexamethasone Drug Implant | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.151 | Olanzapine Oral | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.152 | Olanzapine Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.153 | Idarubicin Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.154 | Neurokinin 1 Receptor Antagonist Ingredient | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.155 | Serotonin Receptor Antagonist Ingredient | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.156 | Clofarabine Injectable | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.157 | Belinostat Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.158 | Bortezomib Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159 | Cabazitaxel Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.160 | Carfilzomib Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.161 | Decitabine Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.162 | Elotuzumab Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.163 | Enfortumab Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.164 | Eribulin Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.165 | Etoposide Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.166 | Inotuzumab Ozogamicin Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.167 | Mitoxantrone Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.168 | Moxetumomab Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.169 | Necitumumab Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.170 | Nelarabine Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.171 | Temsirolimus Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.172 | Tisagenlecleucel Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.173 | Topotecan Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178 | Atezolizumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179 | Avelumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.180 | Bleomycin Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181 | Cemiplimab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.182 | Cladribine Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.183 | Daratumumab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184 | Durvalumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.185 | Emapalumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.186 | Fludarabine Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187 | Ipilimumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188 | Nivolumab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189 | Pembrolizumab Injectable | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.190 | Polatuzumab Vedotin Injectable | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.191 | Pralatrexate Injectable | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.192 | Vincristine Injectable | active | 2021-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.193 | Methotrexate Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.194 | Trastuzumab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.195 | Mitomycin Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196 | Brentuximab Vedotin Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.197 | Doxorubicin Pegylated Liposomal Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.198 | Blinatumomab Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.199 | Trastuzumab Emtansine Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.200 | Gemtuzumab Ozogamicin Injectable | active | 2021-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.201 | Tagraxofusp Injectable | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.202 | Axicabtagene Ciloleucel Injectable | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.203 | BRCA1 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.204 | BRCA2 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.205 | BRCA1 Testing | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.207 | Epithelial Ovarian Cancer | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.208 | Primary Peritoneal Cancer | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.209 | Fallopian Tube Cancer | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.210 | Multigene Panel | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.211 | BRCA1 and BRCA2 | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.212 | BRCA1 and BRCA2 Testing | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.213 | BRAF V600 | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.214 | BRAF V600 Testing | active | 2023-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.215 | Colorectal Cancer | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.216 | BRAF V600 Mutation Status | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.217 | Cancer Stage I | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.218 | Head and Neck Cancer | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.219 | Malignant Melanoma of Skin | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.220 | Brain Cancer | active | 2022-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.221 | Waldenstrom Macroglobulinemia | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.222 | High Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.223 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.224 | Docetaxel Injectable | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.225 | Cyclophosphamide Injectable | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226 | LAG 3 Inhibitor | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.227 | Neoplasm of Brain | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.233 | Chemotherapy Administration | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.240 | Pathological N Stage N3c | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.241 | Audio Visual Telehealth Encounter | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.242 | Moderate or High Emetic Risk Oral Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.243 | Minimal to Low Emetic Risk Oral Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.244 | Copanlisib Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.245 | Isatuximab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.246 | Loncastuximab tesirine Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.247 | Margetuximab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.248 | Mirvetuximab soravtansine Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.249 | Tafasitamab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.250 | Teclistamab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.251 | Tisotumab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.252 | Asparaginase Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.254 | Belantamab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.255 | Dostarlimab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.256 | Mosunetuzumab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.257 | Tremelimumab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.258 | Indication for Dexamethasone | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.260 | Indication for Olanzapine | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.261 | Indication for Dexamethasone | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.263 | Indication for Olanzapine | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.264 | Prednisone | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.265 | As Needed PRN | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.266 | Amivantamab Injectable | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.200 | Doxorubicin | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201 | Epirubicin | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.202 | Capecitabine | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.203 | Cyclophosphamide | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.204 | Injectable Fluorouracil | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.205 | Methotrexate | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.206 | Trastuzumab and Biosimilars | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.207 | HER2 Presence in Tissue | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.208 | Carboplatin | active | 2020-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.209 | Depression Screening for Adult | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.210 | Long Acting Opioids | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.211 | High Fiber Supplement or Diet Education | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.212 | Dexamethasone | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.213 | Olanzapine | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.214 | Pancreatic Cancer | active | 2020-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.215 | Audio Visual Telehealth Encounter | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.216 | Telephone Encounter | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.217 | Telehealth Emergency Department or Initial Inpatient | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.218 | Dyspnea Assessment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.219 | Nausea or Vomiting Assessment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.220 | Karnofsky Performance Status | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.221 | Referral to Hospice Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.222 | Referral to Palliative Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.223 | Palliative Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.224 | Enrollment in Hospice Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.225 | Advance Directive Including Durable Power of Attorney or Instructional | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.228 | Low Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.229 | Minimal Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.232 | Epithelial Ovarian Cancer | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.233 | Primary Peritoneal Cancer | active | 2022-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.235 | BRCA2 Testing | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.236 | Multigene Panel | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.237 | BRCA1 Testing | active | 2023-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238 | First Line Drug Therapy for Metastatic Colorectal Cancer | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.239 | BRAF V600 Testing | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.240 | Cancer Stage 4 | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.241 | Cancer Stage M1 | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.242 | High Emetic Risk Intravenous Antineoplastic Agent | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.243 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.244 | Anthracycline Injectable | active | 2024-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.245 | Antiemetic Agent | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.247 | Indication for Dexamethasone | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.249 | Indication for Olanzapine | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.3 | Race Category Excluding Nulls | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1 | Abdomen CT without contrast | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.11 | Oxycodone | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.12 | Oxymorphone | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.70 | Morphine | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.71 | Methadone Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.72 | Meperidine | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.73 | Levorphanol | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.74 | Hydromorphone | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.75 | Hydrocodone | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.76 | Fentanyl | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.77 | Codeine | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.12 | Butorphanol | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.13 | Dihydrocodeine | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.14 | Nalbuphine | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.15 | Opium Combinations | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.16 | Pentazocine | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.17 | Tapentadol | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.18 | Tramadol | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1017 | Adrenal Mass | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1019 | Diseases of Urinary System | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1020 | Hematuria | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1021 | Infections of Kidney | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1022 | Jaundice | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1023 | Liver Lesion (Mass or Neoplasm) | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1024 | Malignant Neoplasm of Bladder | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1025 | Malignant Neoplasm of Pancreas | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1026 | Non Traumatic Aortic Disease | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1028 | Unspecified Disorder of Kidney and Ureter | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1301 | Surgery Integumentary System Breast | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1302 | Surgery Respiratory System Accessory Sinuses | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1303 | Surgery Respiratory System Larynx | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1304 | Surgery Respiratory System Trachea and Bronchi | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1305 | Surgery Respiratory System Lungs and Pleura | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13064 | Surgery Digestive System Esophagus | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1307 | Surgery Digestive System Intestines (Except Rectum) | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1308 | Surgery Digestive System Rectum | active | 2019-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1309 | Surgery Digestive System Anus | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1310 | Surgery Digestive System Biliary Tract | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1311 | Surgery Digestive System Abdomen Peritoneum Omentum | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1312 | Surgery Digestive System Kidney | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13133 | Surgery Digestive System Ureter | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1314 | Surgery Digestive System Bladder | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1315 | Surgery Female Genital System Cervix Uteri | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1316 | Surgery Female Genital System Corpus Uteri | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1317 | Surgery Female Genital System Oviduct Ovary | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1318 | Surgery Eye and Ocular Adnexa Anterior Segment | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13193 | Other Surgeries | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13202 | SPECT MPI | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13213 | Stress Echocardiography | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13222 | Stress MRI | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1323 | CCTA | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1329 | Diabetes Mellitus | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1330 | Renal insufficiency | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1331 | Stroke transient ischemic attack | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1332 | Prior heart failure | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1333 | Ischemic heart disease | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1802 | Physical Therapy | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1803 | Chiropractic Evaluation | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1804 | Claim(s) for evaluation and management > 28 days and <60 days preceding the lumbar spine MRI | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1805 | MRI Lumbar Spine Procedures | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1809 | Other Deforming Dorsopathies | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1810 | Spondylopathies | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1811 | Other Dorsopathies | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1812 | Biomechanical Lesions (not Elsewhere Classified) | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1813 | Dislocation or Sprain of those Joints and Ligaments Located in the Lumbar Spine or Pelvis | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.18143 | Patients with lumbar spine surgery in the 90 days prior to MRI | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1832 | Cancer | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1833 | Congenital spine and spinal cord malformations | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1834 | Inflammatory and autoimmune disorders | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1835 | Infectious conditions | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1836 | Spinal vascular malformations and/or the cause of occult subarachnoid hemorrhage | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1837 | Spinal cord infarction | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1838 | Neoplastic abnormalities | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1839 | Treatment fields for radiation therapy | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1840 | Spinal abnormalities associated with scoliosis | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1841 | Syringohydromyelia | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1842 | Postoperative fluid collections and soft tissue changes | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1843 | Trauma | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1844 | IV Drug Abuse | active | 2022-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1845 | Neurological Impairment | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1846 | Human Immunodeficiency Virus | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1847 | Unspecified Immune Deficiencies | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190123 | Diagnostic Mammography Study | active | 2018-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1902 | Ultrasound of the Breast | active | 2019-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190412 | Screening Mammography and DBT Studies | active | 2018-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2 | Abdomen CT with contrast | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.1 | Percutaneous Coronary Intervention ICD10 | active | 2018-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.2 | Percutaneous Coronary Intervention SNOMEDCT | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.3 | Percutaneous Coronary Intervention CPT | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.4 | Percutaneous Coronary Intervention HCPCS | active | 2018-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.5 | Percutaneous Coronary Intervention | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.21 | Abdomen CT Without then With Contrast | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4009 | Malignant Intracranial Neoplasm | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4010 | Malignant Intracranial Neoplasm | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4015 | STEMI | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4016 | STEMI | active | 2019-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4017 | STEMI | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019 | Fibrinolytic Therapy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4023 | Cerebral Vascular Lesion | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4024 | Cerebral Vascular Lesion | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4025 | Cerebral Vascular Lesion | active | 2019-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4026 | Closed Head and Facial Trauma | active | 2019-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4028 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4029 | Acute Peptic Ulcer | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4030 | Acute Peptic Ulcer | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4031 | Acute Peptic Ulcer | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4032 | Dementia and Related Intracranial Pathologies | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4033 | Dementia and Related Intracranial Pathologies | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4034 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4035 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4036 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4043 | Dementia and Related Intracranial Pathologies | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4044 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4045 | Oral Anticoagulant Medications | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4046 | Cardiopulmonary Emergency | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4047 | Cardiopulmonary Emergency | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4048 | Cardiopulmonary Emergency | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4049 | Mechanical Circulatory Assist Device | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4050 | Mechanical Circulatory Assist Device | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4052 | Mechanical Circulatory Assist Device | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4053 | Pregnant State | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4054 | Pregnant State | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4055 | Pregnant State | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4056 | Major Surgical Procedure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4057 | Emergency Department Encounter | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4066 | Diagnostic DBT Study | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1005 | Chronic Stable Angina | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1006 | Chronic Stable Angina | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.3.1002 | Chronic Stable Angina | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1001 | Hospice Encounter | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1002 | Hospice Encounter | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 | Hospice Encounter | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1004 | Nutrition Services | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1005 | Nutrition Services | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1006 | Nutrition Services | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1007 | Hospice Care Ambulatory | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1008 | Hospice Care Ambulatory | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005 | Office Visit | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020 | Initial Hospital Inpatient Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030 | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035 | Discharge Services Hospital Inpatient | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040 | Outpatient Consultation | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050 | Emergency Department Evaluation and Management Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060 | Nursing Facility Visit | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065 | Discharge Services Nursing Facility | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080 | Home Healthcare Services | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110 | Preventive Care, Initial Office Visit, 0 to 17 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115 | Preventive Care Services Initial Office Visit, 18 and Up | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120 | Preventive Care, Established Office Visit, 0 to 17 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125 | Preventive Care Services Established Office Visit, 18 and Up | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130 | Preventive Care Services Individual Counseling | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135 | Preventive Care Services Group Counseling | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215 | Referral | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216 | Face-to-Face Interaction | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221 | Behavioral Health Follow up Visit | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222 | Psychotherapy and Pharmacologic Management | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228 | Detoxification Visit | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232 | Audiology Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233 | Medical Disability Exam | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260 | Telephone Visits | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261 | Nursing Facility Visit | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262 | Care Services in Long Term Residential Facility | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264 | Office Visit | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265 | Home Healthcare Services | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266 | Outpatient Consultation | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276 | Frailty Encounter | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277 | Outpatient Encounter | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278 | Outpatient Encounter | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279 | Frailty Encounter | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1281 | Virtual Encounter | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1282 | Virtual Encounter | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284 | Outpatient Encounter | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285 | Palliative Encounter | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286 | Palliative Encounter | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287 | Telephone Visits | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 | Office Visit | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004 | Initial Hospital Inpatient Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006 | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007 | Discharge Services Hospital Inpatient | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 | Outpatient Consultation | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1010 | Emergency Department Evaluation and Management Visit | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1012 | Nursing Facility Visit | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1013 | Discharge Services Nursing Facility | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1014 | Care Services in Long Term Residential Facility | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1016 | Home Healthcare Services | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1022 | Preventive Care Services, Initial Office Visit, 0 to 17 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 | Preventive Care Services Initial Office Visit, 18 and Up | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1024 | Preventive Care, Established Office Visit, 0 to 17 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 | Preventive Care Services Established Office Visit, 18 and Up | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 | Preventive Care Services Individual Counseling | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1027 | Preventive Care Services Group Counseling | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1046 | Referral | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1048 | Face-to-Face Interaction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1054 | Behavioral Health Follow up Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1055 | Psychotherapy and Pharmacologic Management | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1059 | Detoxification Visit | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1066 | Audiology Visit | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1073 | Medical Disability Exam | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1080 | Telephone Visits | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1087 | Outpatient Encounter | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1088 | Frailty Encounter | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1089 | Virtual Encounter | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 | Palliative Care Encounter | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1010 | Multiple Myeloma | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1011 | Multiple Myeloma | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1012 | Premature Menopause | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1013 | Premature Menopause | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1014 | Multiple Myeloma | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1015 | Premature Menopause | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1019 | Amenorrhea | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1031 | Acute Pharyngitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1033 | Acute Pharyngitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1034 | Acute Tonsillitis | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1036 | Acute Tonsillitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1058 | Upper Respiratory Infection | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1059 | Upper Respiratory Infection | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1066 | Comorbid Conditions for Respiratory Conditions | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1067 | Comorbid Conditions for Respiratory Conditions | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1011 | Acute Pharyngitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1012 | Acute Tonsillitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1017 | Competing Conditions for Respiratory Conditions | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1022 | Upper Respiratory Infection | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1025 | Comorbid Conditions for Respiratory Conditions | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1021 | Amenorrhea | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1022 | Amenorrhea | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1025 | Bilateral Oophorectomy | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1026 | Unilateral Oophorectomy Left | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1028 | Unilateral Oophorectomy Left | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1029 | Unilateral Oophorectomy Left | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 | Diabetes | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1020 | Type 1 Diabetes | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1030 | Unilateral Oophorectomy Right | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1031 | Unilateral Oophorectomy Right | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1032 | Unilateral Oophorectomy Right | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1034 | Unilateral Oophorectomy, Unspecified Laterality | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1035 | Unilateral Oophorectomy, Unspecified Laterality | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1036 | Eating Disorders | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1038 | Eating Disorders | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1039 | Eating Disorders | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1029 | Essential Hypertension | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1031 | Essential Hypertension | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.12.1011 | Essential Hypertension | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1040 | Major Transplant | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1042 | Major Transplant | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1043 | Potentially Harmful Antihistamines for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1046 | Evidence of Bilateral Oophorectomy | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1048 | Evidence of Bilateral Oophorectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1049 | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1010 | Mental Health Diagnoses | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1012 | Mental Health Diagnoses | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1017 | Major Depression | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1019 | Major Depression | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1060 | Major Depression In Remission | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1062 | Major Depression In Remission | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1161 | Schizophrenia or Psychotic Disorder | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1162 | Schizophrenia or Psychotic Disorder | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1163 | Schizophrenia or Psychotic Disorder | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1178 | Pervasive Developmental Disorder | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1180 | Pervasive Developmental Disorder | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1206 | Mental Behavioral and Neurodevelopmental Disorders | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1207 | Mental Behavioral and Neurodevelopmental Disorders | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1210 | Schizophrenia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1211 | Schizophrenia | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1212 | Seizure Disorder | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1213 | Seizure Disorder | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1214 | REM | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1215 | REM | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1216 | Benzodiazepine Withdrawal | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1217 | Benzodiazepine Withdrawal | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1218 | Alcohol Withdrawal | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1219 | Alcohol Withdrawal | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1220 | General Anxiety | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1221 | General Anxiety | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1004 | Mental Health Diagnoses | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1007 | Major Depression | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1104 | Schizophrenia or Psychotic Disorder | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1152 | Pervasive Developmental Disorder | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1203 | Mental Behavioral and Neurodevelopmental Disorders | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1205 | Schizophrenia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1206 | Seizure Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1207 | REM Sleep Behavior Disorder | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1208 | Benzodiazepine Withdrawal | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1209 | Alcohol Withdrawal | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1210 | Generalized Anxiety Disorder | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1050 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1051 | Dipyridamole Medications | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1053 | Nifedipine Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1054 | Potentially Harmful Antidepressants for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1055 | Potentially Harmful Barbiturates for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1057 | Meprobamate Medications | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1058 | Potentially Harmful Estrogens for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1059 | Potentially Harmful Sulfonylureas for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1001 | Substance Use Disorder | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1003 | Substance Use Disorder | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1012 | Substance Use Disorder Treatment | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1036 | Substance Use Disorder Treatment | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1001 | Substance Use Disorder | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1005 | Substance Use Disorder Treatment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1060 | Desiccated Thyroid Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1062 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1063 | Potentially Harmful Pain Medications for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1065 | Digoxin Medications | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1066 | Digoxin Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1067 | Doxepin Medications | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1068 | Doxepin Medications | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1001 | Malignant Neoplasm of Colon | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1003 | Malignant Neoplasm of Colon | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1025 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1027 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1044 | Pap Test | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1047 | Mammography | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1051 | Colonoscopy | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1052 | Colonoscopy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1053 | Colonoscopy | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1145 | sDNA FIT Test | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1001 | Malignant Neoplasm of Colon | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1009 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1017 | Pap Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1018 | Mammography | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1020 | Colonoscopy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1038 | CT Colonography | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1039 | sDNA FIT Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1024 | Kidney Transplant | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1025 | Kidney Transplant | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1026 | Dialysis Services | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1027 | Dialysis Services | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1028 | Dialysis Services | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1029 | ESRD Monthly Outpatient Services | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1052 | Kidney Transplant | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1060 | Kidney Transplant Recipient | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1067 | Kidney Transplant | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1012 | Kidney Transplant | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1013 | Dialysis Services | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1014 | ESRD Monthly Outpatient Services | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1029 | Kidney Transplant Recipient | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1065 | DTaP Vaccine Administered | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1066 | DTaP Vaccine Administered | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1068 | Hepatitis A | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1070 | Hepatitis A | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1078 | Measles | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1080 | Measles | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1085 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1086 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1087 | Mumps | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1089 | Mumps | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1098 | Rubella | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.110 | Rubella | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1104 | Varicella Zoster | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1105 | Varicella Zoster | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1106 | Varicella Zoster Vaccine (VZV) Administered | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1107 | Varicella Zoster Vaccine (VZV) Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1109 | Hepatitis A Vaccine Administered | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1110 | Hepatitis A Vaccine Administered | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1111 | Hepatitis B Vaccine Administered | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1112 | Hepatitis B Vaccine Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1115 | Child Influenza Vaccine Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1116 | Child Influenza Vaccine Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1117 | Inactivated Polio Vaccine (IPV) Administered | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1118 | Inactivated Polio Vaccine (IPV) Administered | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1119 | Pneumococcal Conjugate Vaccine Administered | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1120 | Rotavirus Vaccine (3 dose schedule) Administered | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1121 | Rotavirus Vaccine (2 dose schedule) Administered | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1123 | Genital Herpes | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1124 | Genital Herpes | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1128 | Lab Tests for Sexually Transmitted Infections | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1129 | Chlamydia Screening | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1133 | Pneumococcal Conjugate Vaccine Administered | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1135 | HPV Test | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1148 | Rotavirus Vaccine (2 Dose Schedule) Administered | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1149 | Rotavirus Vaccine (3 Dose Schedule) Administered | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1150 | Advanced Illness | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1151 | Advanced Illness | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1152 | HiB Vaccine (3 dose schedule) | active | 2021-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1153 | HiB Vaccine (3 dose schedule) Administered | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1154 | HiB Vaccine (4 dose schedule) | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1155 | HiB Vaccine (4 dose schedule) Administered | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1156 | HiB Vaccine (3 dose schedule) Administered | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1157 | HiB Vaccine (4 dose schedule) Administered | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1158 | Competing Conditions for Respiratory Conditions | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1159 | Competing Conditions for Respiratory Conditions | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1022 | DTaP Vaccine Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 | Hepatitis A | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1031 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1032 | Mumps | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1037 | Rubella | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1039 | Varicella Zoster | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1040 | Varicella Zoster Vaccine (VZV) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1041 | Hepatitis A Vaccine Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1042 | Hepatitis B Vaccine Administered | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1044 | Child Influenza Vaccine Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1045 | Inactivated Polio Vaccine (IPV) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1046 | Pneumococcal Conjugate Vaccine Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1047 | Rotavirus Vaccine (3 dose schedule) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1048 | Rotavirus Vaccine (2 dose schedule) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1049 | Genital Herpes | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1051 | Lab Tests for Sexually Transmitted Infections | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1052 | Chlamydia Screening | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1053 | Measles | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1059 | HPV Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1082 | Advanced Illness | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1083 | Hib Vaccine (3 dose schedule) | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1084 | Hib Vaccine (3 dose schedule) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1085 | Hib Vaccine (4 dose schedule) | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1086 | Hib Vaccine (4 dose schedule) Administered | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1087 | Influenza Virus LAIV Vaccine | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1088 | Influenza Virus LAIV Vaccine Administered | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1012 | Lab Tests During Pregnancy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1013 | Diagnostic Studies During Pregnancy | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1019 | Pregnancy Test | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1022 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1023 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1028 | Procedures for Sexual Activity | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1030 | Procedures for Sexual Activity | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1031 | Diagnosis for Sexual Activity | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1032 | Diagnosis for Sexual Activity | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1033 | Procedures for Sexual Activity | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1007 | Lab Tests During Pregnancy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1008 | Diagnostic Studies During Pregnancy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1011 | Pregnancy Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1012 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1016 | Congenital or Acquired Absence of Cervix | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1017 | Procedures Used to Indicate Sexual Activity | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1018 | Diagnoses Used to Indicate Sexual Activity | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1024 | Absence of Cervix | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1025 | Absence of Cervix | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1026 | Absence of Cervix | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1073 | Osteoporosis Without Current Fracture | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1074 | Osteoporosis Without Current Fracture | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1078 | History of hip fracture in parent | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1080 | Rheumatoid Arthritis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1081 | Rheumatoid Arthritis | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1083 | Central DXA of Hip or Spine | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1085 | Osteogenesis Imperfecta | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1087 | Osteogenesis Imperfecta | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1088 | Ankylosing Spondylitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090 | Ankylosing Spondylitis | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1091 | Psoriatic Arthritis | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1093 | Psoriatic Arthritis | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1094 | Ehlers Danlos Syndrome | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1096 | Ehlers Danlos Syndrome | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1097 | Marfan's Syndrome | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1099 | Marfan's Syndrome | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1100 | Osteopenia | active | 2018-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1102 | Osteopenia | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1200 | Osteoporosis With Current Fracture | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1201 | Osteoporosis With Current Fracture | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1202 | DXA (Dual energy Xray Absorptiometry) Scan Non Hip or Spine | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1308 | Frailty Diagnosis | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1309 | Frailty Diagnosis | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1310 | Frailty Symptom | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1311 | Frailty Symptom | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1005 | Rheumatoid Arthritis | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1038 | Osteoporosis Without Current Fracture | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1040 | History of hip fracture in parent | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1044 | Osteogenesis Imperfecta | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1045 | Ankylosing Spondylitis | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1046 | Psoriatic Arthritis | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1047 | Ehlers Danlos Syndrome | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1048 | Marfan's Syndrome | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1049 | Osteopenia | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1050 | Osteoporosis With Current Fracture | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1051 | DXA (Dual energy Xray Absorptiometry) Scan | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1074 | Frailty Diagnosis | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1075 | Frailty Symptom | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1021 | Narcolepsy | active | 2018-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1023 | Narcolepsy | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1024 | Neurologic impairment | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1025 | Neurologic impairment | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1026 | Neurologic impairment | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1011 | Narcolepsy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1012 | Neurologic impairment | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1149 | Substance Use Disorder Long Acting Medication | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.11.1248 | Retinal or Dilated Eye Exam | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.12.1088 | Retinal or Dilated Eye Exam | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1150 | Substance Use Disorder Short Acting Medication | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1151 | Substance Use Disorder Long Acting Medication Administration | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1152 | Substance Use Disorder Short Acting Medication Administration | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1155 | Substance Use Disorder Short Acting Medication Administration | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1156 | Substance Use Disorder Long Acting Medication Administration | active | 2021-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1157 | Substance Use Disorder Short Acting Medication Administration | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1163 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1164 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 | Hospice Diagnosis | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1166 | Hospice Diagnosis | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 | Palliative Care Diagnosis | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1168 | Palliative Care Diagnosis | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1169 | Palliative Care Diagnosis | active | 2022-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1023 | Cushings Syndrome | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1025 | Cushings Syndrome | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1026 | Lupus | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1028 | Lupus | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1031 | Hyperthyroidism | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1033 | Hyperthyroidism | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1034 | Hyperparathyroidism | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1036 | Hyperparathyroidism | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1009 | Cushings Syndrome | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1010 | Lupus | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1015 | Hyperthyroidism | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1016 | Hyperparathyroidism | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1170 | Atomoxetine | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1171 | Clonidine | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1172 | Dexmethylphenidate | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1173 | Dextroamphetamine | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1174 | Lisdexamfetamine | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1176 | Methylphenidate | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1177 | Lower Body Fractures Excluding Ankle and Foot | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1178 | Lower Body Fractures Excluding Ankle and Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1179 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1042 | Counseling for Physical Activity | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1077 | Falls Screening | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1097 | CT Colonography | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1220 | Frailty Device SNOMED | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1028 | Falls Screening | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1035 | Counseling for Physical Activity | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1300 | Frailty Device | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1180 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1181 | Mechanical Complications Excluding Upper Body | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1182 | Mechanical Complications Excluding Upper Body | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1183 | Partial Arthroplasty of Hip | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1184 | Partial Arthroplasty of Hip | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1188 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2022-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1189 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1190 | Antibiotic Medications for Upper Respiratory Infection | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1193 | Malignant Neoplasms | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1194 | Malignant Neoplasms | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1196 | Atherosclerosis of the Extremities | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1197 | Atherosclerosis of the Extremities | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1198 | Atherosclerosis of the Extremities | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1199 | Lower Extremity Neurological Assessment Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1001 | Disorders of the Immune System | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1003 | Disorders of the Immune System | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1004 | HIV Viral Load | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1005 | HIV 1 | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1007 | HIV 1 | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1008 | HIV 2 | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1010 | HIV 2 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1011 | Severe Combined Immunodeficiency | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1012 | Severe Combined Immunodeficiency | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1001 | Disorders of the Immune System | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1002 | HIV Viral Load | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 | HIV | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1007 | Severe Combined Immunodeficiency | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1200 | Lower Extremity Neurological Tests | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1201 | Lower Extremity Visual Inspection Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1202 | Lower Extremity Visual Inspection Test | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1203 | Monofilament Test Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1204 | Monofilament Tests | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1205 | Pedal Pulse Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1206 | Peripheral Neuropathy | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1207 | Peripheral Neuropathy | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1208 | Peripheral Neuropathy | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1209 | Amputation of Bilateral Feet | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1011 | Consultant Report | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1028 | BMI percentile | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1030 | Height | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1031 | Weight | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1006 | Consultant Report | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1012 | BMI percentile | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1014 | Height | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1015 | Weight | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1210 | Amputation of Bilateral Feet | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1211 | Amputation of Bilateral Feet | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1212 | Amputation of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1213 | Amputation of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1214 | Amputation of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1215 | Amputation of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1216 | Amputation of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1217 | Amputation of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1218 | Amputation of Unspecified Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1219 | Amputation of Unspecified Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.11.1003 | Ambulatory | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.12.1003 | Ambulatory | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1220 | Foot Assessment With Abnormal Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1221 | Foot Assessment With Abnormal Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1222 | Acquired Absence of Bilateral feet | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1223 | Acquired Absence of Bilateral feet | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1224 | Acquired Absence of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1225 | Acquired Absence of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1226 | Acquired Absence of Left Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1227 | Acquired Absence of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1228 | Acquired Absence of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1229 | Acquired Absence of Right Foot | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1230 | Lower Body Fractures Excluding Ankle and Foot | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1231 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1232 | Mechanical Complications Excluding Upper Body | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1233 | Partial Arthroplasty of Hip | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1234 | Partial Arthroplasty of Hip | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1235 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1236 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1237 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1238 | Primary THA Procedure | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1239 | Foot Ulcer | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1240 | Foot Ulcer | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1241 | Foot Ulcer | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1242 | Referral for Foot Care | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1243 | Therapeutic Footwear | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1244 | Foot Deformity | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1245 | Foot Deformity | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1246 | Foot Deformity | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1247 | Megestrol Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1248 | Meperidine Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1249 | Potentially Harmful Antidepressants for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1004 | Fluoride Varnish Application for Children | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1007 | Dental Caries | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1009 | Dental Caries | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1010 | Clinical Oral Evaluation | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1011 | Fluoride Varnish Application for Children | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1002 | Fluoride Varnish Application for Children | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1003 | Clinical Oral Evaluation | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1004 | Dental Caries | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1250 | Potentially Harmful Antihistamines for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1251 | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1252 | Potentially Harmful Barbiturates for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1253 | Potentially Harmful Estrogens for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1254 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1255 | Potentially Harmful Pain Medications for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1256 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1257 | Potentially Harmful Sulfonylureas for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1258 | Substance Use Disorder Long Acting Medication | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1259 | Substance Use Disorder Short Acting Medication | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1260 | Viloxazine | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1266 | Diabetic Retinopathy Severity Level | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1272 | Diabetes | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1273 | Diabetes | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1003 | Counseling for Nutrition | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1004 | Counseling for Nutrition | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.12.1003 | Counseling for Nutrition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001 | Antibiotic Medications for Pharyngitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078 | Nifedipine Medications | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080 | Contraceptive Medications | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109 | Meperidine Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129 | Desiccated Thyroid Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143 | Isotretinoin | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167 | Dipyridamole Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205 | Leucovorin | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211 | Aspirin and Other Antiplatelets | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1212 | DTaP Vaccine | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1214 | Hepatitis A Vaccine | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1216 | Hepatitis B Vaccine | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1220 | Child Influenza Vaccine | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1222 | Inactivated Polio Vaccine (IPV) | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1228 | Pneumococcal Conjugate Vaccine | active | 2023-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1232 | Rotavirus Vaccine (3 dose schedule) | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1234 | Varicella Zoster Vaccine (VZV) | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1235 | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252 | Guanfacine Medications | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255 | Megestrol Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256 | Meprobamate Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266 | Aromatase Inhibitors | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267 | Glucocorticoids (oral only) | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482 | Potentially Harmful Antiinfectives for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517 | Dementia Medications | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530 | Antidepressant Medication | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1531 | Potentially Harmful Benzodiazepines for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532 | Potentially Harmful Antipsychotics for Older Adults | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001 | Antibiotic Medications for Pharyngitis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080 | Contraceptive Medications | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143 | Isotretinoin | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1170 | Varicella Zoster Vaccine (VZV) | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205 | Leucovorin | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211 | Aspirin and Other Antiplatelets | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213 | Antidepressant Medication | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1214 | DTaP Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1215 | Hepatitis A Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1216 | Hepatitis B Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1218 | Child Influenza Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1219 | Inactivated Polio Vaccine (IPV) | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1221 | Pneumococcal Conjugate Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1223 | Rotavirus Vaccine (3 dose schedule) | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1224 | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265 | Aromatase Inhibitors | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266 | Glucocorticoids (oral only) | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481 | Potentially Harmful Antiinfectives for Older Adults | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510 | Dementia Medications | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522 | Potentially Harmful Benzodiazepines for Older Adults | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523 | Potentially Harmful Antipsychotics for Older Adults | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1005 | Bilateral Mastectomy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1009 | Primary THA Procedure | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1015 | Flexible Sigmoidoscopy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1016 | Flexible Sigmoidoscopy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1017 | Flexible Sigmoidoscopy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1020 | Fecal Occult Blood Test (FOBT) | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1023 | Group A Streptococcus Test | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1024 | HbA1c Laboratory Test | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1026 | Hysterectomy with No Residual Cervix | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1027 | Hysterectomy with No Residual Cervix | active | 2024-11 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1035 | Total Colectomy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1036 | Total Colectomy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1055 | XRay Study | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1061 | Gastric Bypass Surgery | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1062 | Gastric Bypass Surgery | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1080 | Primary THA Procedure | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1084 | History of bilateral mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1085 | History of bilateral mastectomy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1086 | Status Post Left Mastectomy | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1087 | Status Post Right Mastectomy | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1089 | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1090 | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1091 | Status Post Left Mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1092 | Status Post Right Mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1096 | Major Transplant | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1097 | Major Transplant | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1132 | Unilateral Mastectomy Left | active | 2021-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1133 | Unilateral Mastectomy Right | active | 2021-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1134 | Hysterectomy with No Residual Cervix | active | 2023-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1135 | Hysterectomy with No Residual Cervix | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1140 | Bilateral Mastectomy | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1143 | Total Colectomy | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1144 | Unilateral Mastectomy Left | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1145 | Unilateral Mastectomy Right | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1148 | Palliative Intervention | active | 2023-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1005 | Bilateral Mastectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1006 | Primary THA Procedure | active | 2023-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1010 | Flexible Sigmoidoscopy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1011 | Fecal Occult Blood Test (FOBT) | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1012 | Group A Streptococcus Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1013 | HbA1c Laboratory Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1014 | Hysterectomy with No Residual Cervix | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1019 | Total Colectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1034 | XRay Study | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1050 | Gastric Bypass Surgery | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1068 | History of bilateral mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1069 | Status Post Left Mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1070 | Status Post Right Mastectomy | active | 2017-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1071 | Unilateral Mastectomy, Unspecified Laterality | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1075 | Major Transplant | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1133 | Unilateral Mastectomy Left | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1134 | Unilateral Mastectomy Right | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 | Palliative Care Intervention | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1064 | Anaphylactic Reaction to DTaP Vaccine | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1065 | Chronic Liver Disease | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1067 | Chronic Liver Disease | active | 2022-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1068 | Chronic Malnutrition | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1070 | Chronic Malnutrition | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1100 | Malabsorption Syndromes | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1102 | Malabsorption Syndromes | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1105 | Intussusception | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1106 | Intussusception | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1107 | Influenza Virus LAIV Vaccine | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1108 | Influenza Virus LAIV Vaccine Administered | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1031 | Anaphylactic Reaction to DTaP Vaccine | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1035 | Chronic Liver Disease | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1036 | Chronic Malnutrition | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1050 | Malabsorption Syndromes | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1056 | Intussusception | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2446 | Lower Extremity Visual Inspection Test | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2447 | Pedal Pulse Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2448 | Monofilament Test Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2449 | Monofilament Tests | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2450 | Lower Extremity Neurological Assessment Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2451 | Lower Extremity Neurological Tests | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2452 | Lower Extremity Visual Inspection Result or Finding | active | 2023-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2616 | Autonomous Eye Exam Result or Finding | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.1577 | Pharmacologic Therapy for Hypertension | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1036 | Chronic Kidney Disease, Stage 5 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1037 | Chronic Kidney Disease, Stage 5 | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1049 | Patient Provider Interaction | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1058 | Psych Visit for Family Psychotherapy | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1062 | Physical Therapy Evaluation | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1063 | Occupational Therapy Evaluation | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1064 | Neurobehavioral Status Exam (CPT) | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1067 | Dementia and Mental Degenerations | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1068 | Dementia and Mental Degenerations | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1069 | Standardized Tools for Assessment of Cognition | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1071 | Radiation Treatment Management | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1072 | Radiation Treatment Management | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1073 | Standardized Pain Assessment Tool | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1078 | Cancer | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1079 | Cancer | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1080 | Chemotherapy Administration | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1081 | Chemotherapy Administration | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.111 | Ophthalmological Services | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.113 | Prostate Cancer Treatment | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.118 | Initial Myocardial Infarction | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.119 | Initial Myocardial Infarction | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.120 | Coronary Artery Disease No MI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1238 | Ejection Fraction | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1243 | Psychoanalysis | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1244 | Renal Failure Due to ACE Inhibitor | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1251 | Group Psychotherapy | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1256 | Allergy to ACE Inhibitor or ARB | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1257 | Intolerance to ACE Inhibitor or ARB | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.133 | Beta Blocker Therapy | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1333 | Allergy to Beta Blocker Therapy | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1334 | Intolerance to Beta Blocker Therapy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1341 | Heart Rate | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1342 | Beta Blocker Therapy for LVSD | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1344 | Acute and Subacute Iridocyclitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1353 | Limited Life Expectancy | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1363 | Annual Wellness Visit | active | 2023-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1364 | Macular Exam | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1372 | Tobacco Use Screening | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1374 | Bone Scan | active | 2018-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1377 | Level of Severity of Retinopathy Findings | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1381 | Macular Edema Findings Present | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1401 | Cognitive Assessment | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1402 | Cup to Disc Ratio | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1403 | Optic Disc Exam for Structural Abnormalities | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1509 | Acute and Subacute Iridocyclitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1521 | Burn Confined to Eye and Adnexa | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1523 | Burn Confined to Eye and Adnexa | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1524 | Cataract Secondary to Ocular Disorders | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1526 | Cataract Secondary to Ocular Disorders | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1527 | Cataract Surgery | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1528 | Cataract Surgery | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1529 | Cataract Congenital | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1530 | Cataract Congenital | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1532 | Cataract Mature or Hypermature | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1534 | Cataract Mature or Hypermature | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1535 | Cataract Posterior Polar | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1537 | Cataract Posterior Polar | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1538 | Certain Types of Iridocyclitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1540 | Certain Types of Iridocyclitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1542 | Chronic Iridocyclitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1543 | Chronic Iridocyclitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1544 | Cloudy Cornea | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1546 | Cloudy Cornea | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1548 | Corneal Edema | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1549 | Corneal Edema | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1550 | Disorders of Cornea Including Corneal Opacity | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1552 | Disorders of Cornea Including Corneal Opacity | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1561 | Glaucoma | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1562 | Glaucoma | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1564 | Hereditary Corneal Dystrophies | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1566 | Hereditary Corneal Dystrophies | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1571 | Hypotony of Eye | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1572 | Hypotony of Eye | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1574 | Injury to Optic Nerve and Pathways | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1575 | Injury to Optic Nerve and Pathways | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1577 | Central Corneal Ulcer | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1578 | Central Corneal Ulcer | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1582 | Open Wound of Eyeball | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1583 | Open Wound of Eyeball | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1587 | Pathologic Myopia | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1588 | Pathologic Myopia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1590 | Posterior Lenticonus | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1591 | Posterior Lenticonus | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1601 | Retrolental Fibroplasias | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1603 | Retrolental Fibroplasias | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1612 | Traumatic Cataract | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1613 | Traumatic Cataract | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1615 | Uveitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1617 | Uveitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1618 | Vascular Disorders of Iris and Ciliary Body | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1620 | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1621 | Visual Field Defects | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1623 | Visual Field Defects | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1626 | Amblyopia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1628 | Amblyopia | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1632 | Choroidal Degenerations | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1634 | Choroidal Degenerations | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1635 | Choroidal Detachment | active | 2024-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1637 | Choroidal Detachment | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1638 | Choroidal Hemorrhage and Rupture | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1640 | Choroidal Hemorrhage and Rupture | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1641 | Degeneration of Macula and Posterior Pole | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1643 | Degeneration of Macula and Posterior Pole | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1644 | Degenerative Disorders of Globe | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1646 | Degenerative Disorders of Globe | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1647 | Diabetic Macular Edema | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1649 | Diabetic Macular Edema | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1653 | Disorders of Optic Chiasm | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1655 | Disorders of Optic Chiasm | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1656 | Disorders of Visual Cortex | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1658 | Disorders of Visual Cortex | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1659 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1661 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1662 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1664 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1665 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1667 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1668 | Hereditary Choroidal Dystrophies | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1670 | Hereditary Choroidal Dystrophies | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1671 | Hereditary Retinal Dystrophies | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1673 | Hereditary Retinal Dystrophies | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1677 | Nystagmus and Other Irregular Eye Movements | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1679 | Nystagmus and Other Irregular Eye Movements | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.168 | Cardiac Surgery | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1680 | Optic Atrophy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1682 | Optic Atrophy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1683 | Optic Neuritis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1685 | Optic Neuritis | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1686 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1688 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1689 | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.169 | Cardiac Surgery | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1691 | Other Background Retinopathy and Retinal Vascular Changes | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1695 | Other Disorders of Optic Nerve | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1697 | Other Disorders of Optic Nerve | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1701 | Other Endophthalmitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1703 | Other Endophthalmitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1707 | Prior Penetrating Keratoplasty | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1709 | Prior Penetrating Keratoplasty | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1713 | Purulent Endophthalmitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1715 | Purulent Endophthalmitis | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1716 | Retinal Detachment with Retinal Defect | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1718 | Retinal Detachment with Retinal Defect | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1719 | Retinal Vascular Occlusion | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1721 | Retinal Vascular Occlusion | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1722 | Other Proliferative Retinopathy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1724 | Other Proliferative Retinopathy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1728 | Separation of Retinal Layers | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1730 | Separation of Retinal Layers | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1731 | Visual Acuity 20/40 or Better | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.175 | Hypotension | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1752 | Speech and Hearing Evaluation | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.176 | Arrhythmia | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1766 | Morgagnian Cataract | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1767 | Morgagnian Cataract | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1769 | Macular Scar of Posterior Polar | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.177 | Atrioventricular Block | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1770 | Macular Scar of Posterior Polar | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1771 | Ophthalmological Services | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1772 | Annual Wellness Visit | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1773 | Speech and Hearing Evaluation | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1774 | Occupational Therapy Evaluation | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1775 | Behavioral Neuropsych Assessment | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1776 | Psych Visit Diagnostic Evaluation | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1777 | Psych Visit Psychotherapy | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1778 | Psychoanalysis | active | 2019-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1779 | Group Psychotherapy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.178 | Cardiac Pacer in Situ | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1780 | Psych Visit for Family Psychotherapy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1781 | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1782 | Physical Therapy Evaluation | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.180 | Hypotension | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.181 | Arrhythmia | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.183 | Cardiac Pacer in Situ | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.185 | Hypotension | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.186 | Arrhythmia | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.187 | Atrioventricular Block | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1912 | Major Depressive Disorder Active | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1918 | Major Depressive Disorder Active | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1921 | Beta Blocker Therapy Ingredient | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1923 | Psych Visit Diagnostic Evaluation | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1924 | Cardiac Pacer in Situ | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.408 | Bradycardia | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.410 | Bradycardia | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.411 | Bradycardia | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.422 | Tobacco User | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.423 | Tobacco Use Cessation Pharmacotherapy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.424 | Tobacco Use Cessation Counseling | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.425 | Tobacco Use Cessation Counseling | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.450 | Pain Warranting Further Investigation for Prostate Cancer | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.469 | Bilateral Oophorectomy | active | 2017-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.470 | Bilateral Oophorectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.483 | Chemotherapy | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.484 | Chemotherapy | active | 2021-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.511 | Tobacco Non User | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.532 | Pregnancy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.56 | Coronary Artery Disease No MI | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.57 | Coronary Artery Disease No MI | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.58 | Initial Myocardial Infarction | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.589 | End Stage Renal Disease | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.59 | Asthma | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.590 | End Stage Renal Disease | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.60 | Asthma | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.61 | Asthma | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.73 | Primary Open Angle Glaucoma | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.74 | Primary Open Angle Glaucoma | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.76 | Diabetic Retinopathy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.80 | Diabetic Retinopathy | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.859 | Left Ventricular Systolic Dysfunction | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.860 | Moderate or Severe | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.861 | Moderate or Severe LVSD | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.91 | Prostate Cancer | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.92 | Prostate Cancer | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1002 | Chronic Kidney Disease, Stage 5 | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1005 | Dementia and Mental Degenerations | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1006 | Standardized Tools Score for Assessment of Cognition | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007 | Medical Reason | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1008 | Patient Reason | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1010 | Cancer | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1011 | Occupational Therapy Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1012 | Patient Provider Interaction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1018 | Psych Visit for Family Psychotherapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1022 | Physical Therapy Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1023 | Behavioral or Neuropsych Assessment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1026 | Radiation Treatment Management | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1027 | Chemotherapy Administration | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1028 | Standardized Pain Assessment Tool | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1090 | Moderate or Severe LVSD | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1091 | Left Ventricular Systolic Dysfunction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1092 | Moderate or Severe | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1134 | Ejection Fraction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1139 | ACE Inhibitor or ARB or ARNI | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1140 | Patient Reason for ACE Inhibitor or ARB Decline | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1141 | Psychoanalysis | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1151 | Renal Failure Due to ACE Inhibitor | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1170 | Tobacco User | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1174 | Beta Blocker Therapy | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1176 | Heart Rate | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1177 | Allergy to Beta Blocker Therapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1178 | Intolerance to Beta Blocker Therapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1184 | Beta Blocker Therapy for LVSD | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1187 | Group Psychotherapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1189 | Tobacco Non User | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1190 | Tobacco Use Cessation Pharmacotherapy | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1193 | Cardiac Pacer | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1211 | Allergy to ACE Inhibitor or ARB | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1212 | Intolerance to ACE Inhibitor or ARB | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 | Annual Wellness Visit | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1241 | Acute and Subacute Iridocyclitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1251 | Macular Exam | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1259 | Limited Life Expectancy | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1278 | Tobacco Use Screening | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1283 | Level of Severity of Retinopathy Findings | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1285 | Ophthalmological Services | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1320 | Macular Edema Findings Present | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1332 | Cognitive Assessment | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1333 | Cup to Disc Ratio | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1334 | Optic Disc Exam for Structural Abnormalities | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1409 | Burn Confined to Eye and Adnexa | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1410 | Cataract Secondary to Ocular Disorders | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1411 | Cataract Surgery | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1412 | Cataract Congenital | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1413 | Cataract Mature or Hypermature | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1414 | Cataract Posterior Polar | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1415 | Certain Types of Iridocyclitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1416 | Chronic Iridocyclitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1417 | Cloudy Cornea | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1418 | Corneal Edema | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1419 | Disorders of Cornea Including Corneal Opacity | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1423 | Glaucoma | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1424 | Hereditary Corneal Dystrophies | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1426 | Hypotony of Eye | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1427 | Injury to Optic Nerve and Pathways | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1428 | Central Corneal Ulcer | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1430 | Open Wound of Eyeball | active | 2021-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1432 | Pathologic Myopia | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1433 | Posterior Lenticonus | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1438 | Retrolental Fibroplasias | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1443 | Traumatic Cataract | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1444 | Uveitis | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1445 | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1446 | Visual Field Defects | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1448 | Amblyopia | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1450 | Choroidal Degenerations | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1451 | Choroidal Detachment | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1452 | Choroidal Hemorrhage and Rupture | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1453 | Degeneration of Macula and Posterior Pole | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1454 | Degenerative Disorders of Globe | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1455 | Diabetic Macular Edema | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1457 | Disorders of Optic Chiasm | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1458 | Disorders of Visual Cortex | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1459 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1460 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1461 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1462 | Hereditary Choroidal Dystrophies | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1463 | Hereditary Retinal Dystrophies | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1465 | Nystagmus and Other Irregular Eye Movements | active | 2021-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1466 | Optic Atrophy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1467 | Optic Neuritis | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1468 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1469 | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1471 | Other Disorders of Optic Nerve | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1473 | Other Endophthalmitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1475 | Prior Penetrating Keratoplasty | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1477 | Purulent Endophthalmitis | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1478 | Retinal Detachment with Retinal Defect | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1479 | Retinal Vascular Occlusion | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1480 | Other Proliferative Retinopathy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1482 | Separation of Retinal Layers | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1483 | Visual Acuity 20/40 or Better | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1489 | ACE Inhibitor or ARB or ARNI Ingredient | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1491 | Major Depressive Disorder Active | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1492 | Psych Visit Diagnostic Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1493 | Beta Blocker Therapy Ingredient | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1496 | Psych Visit Psychotherapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1530 | Speech and Hearing Evaluation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1558 | Morgagnian Cataract | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1559 | Macular Scar of Posterior Polar | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1560 | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1561 | Medications for Above Normal BMI | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1562 | Medications for Below Normal BMI | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1563 | Underweight | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1566 | Adult Depression Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1567 | Adolescent Depression Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1568 | Follow Up for Adult Depression | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1569 | Follow Up for Adolescent Depression | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1570 | Referral for Adolescent Depression | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1571 | Referral for Adult Depression | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 | High Intensity Statin Therapy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 | LDL Cholesterol | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 | Low Intensity Statin Therapy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 | Moderate Intensity Statin Therapy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 | Outpatient Encounters for Preventive Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1578 | Follow Up Within 4 Weeks | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1580 | Referral to Primary Care or Alternate Provider | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1581 | Lifestyle Recommendation | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582 | Patient Declined | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1583 | Referral or Counseling for Alcohol Consumption | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 | Hospice Care Ambulatory | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.3000 | Metformin | active | 2019-12 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 | Prostate Cancer | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.320 | Bone Scan | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.326 | Primary Open Angle Glaucoma | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.327 | Diabetic Retinopathy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 | End Stage Renal Disease | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.362 | Asthma | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.366 | Arrhythmia | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.367 | Atrioventricular Block | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.368 | Cardiac Pacer in Situ | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.369 | Coronary Artery Disease No MI | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.370 | Hypotension | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.371 | Cardiac Surgery | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.376 | Heart Failure | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.378 | Pregnancy | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.398 | Prostate Cancer Treatment | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.399 | Salvage Therapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.401 | Prostate Specific Antigen Test | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.403 | Initial Myocardial Infarction | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.412 | Bradycardia | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.451 | Pain Warranting Further Investigation for Prostate Cancer | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.471 | Bilateral Oophorectomy | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.485 | Chemotherapy | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.509 | Tobacco Use Cessation Counseling | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1498 | Medications for Above Normal BMI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1499 | Medications for Below Normal BMI | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1519 | Follow Up for Above Normal BMI | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1523 | Follow Up for Above Normal BMI | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1524 | Follow Up for BMI Outside Normal Parameters | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1525 | Follow Up for Above Normal BMI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1526 | Follow Up for Above Normal BMI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1527 | Referrals Where Weight Assessment May Occur | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1528 | Follow Up for Below Normal BMI | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1549 | Follow Up for Below Normal BMI | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1550 | Follow Up for Below Normal BMI | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1551 | Follow Up for Below Normal BMI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1578 | Palliative Care | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1579 | Palliative or Hospice Care | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1608 | Encounter to Document Medications | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1609 | Encounter to Document Medications | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1610 | Referrals Where Weight Assessment May Occur | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1751 | Encounter to Evaluate BMI | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1834 | Encounter to Document Medications | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1917 | Encounter to Document Medications | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.695 | Encounter to Evaluate BMI | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.885 | Encounter to Evaluate BMI | active | 2018-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.886 | Encounter to Evaluate BMI | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1475 | Referral to Primary Care or Alternate Provider | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1476 | Pharmacologic Therapy for Hypertension | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1482 | Laboratory Tests for Hypertension | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1497 | Encounter to Screen for Blood Pressure | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1508 | Lifestyle Recommendation | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1509 | Weight Reduction Recommended | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1510 | Weight Reduction Recommended | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1511 | Dietary Recommendations | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1512 | Dietary Recommendations | active | 2025-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1514 | Dietary Recommendations | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1515 | Dietary Recommendations | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1516 | Exercise Class | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1518 | Recommendation to Increase Physical Activity | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1537 | Follow Up Within 4 Weeks | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1538 | Encounter to Screen for Depression | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1914 | Encounter to Screen for Depression | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1915 | Encounter to Screen for Depression | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1916 | Encounter to Screen for Depression | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1918 | Encounter to Screen for Blood Pressure | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.192 | Encounter to Screen for Blood Pressure | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1920 | Encounter to Screen for Blood Pressure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2387 | Overweight or Obese | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2388 | Underweight | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2395 | Finding of Hypertension | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2462 | Laboratory Tests for Hypertension | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2466 | Dental Tooth Extraction | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.259 | Diagnosis of Hypertension | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.261 | Diagnosis of Hypertension | active | 2021-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.263 | Diagnosis of Hypertension | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.467 | Follow Up for Adolescent Depression | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.468 | Follow Up for Adult Depression | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.469 | Adolescent Depression Medications | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.470 | Adult Depression Medications | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.537 | Referral for Adolescent Depression | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.538 | Referral for Adult Depression | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.791 | Patient Declined | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.805 | Weight Reduction Recommended | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.810 | Recommendation to Increase Physical Activity | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.823 | Referral or Counseling for Alcohol Consumption | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6366.117 | Absence of Cervix | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1250 | Major Surgical Procedure | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1668 | CABG Surgeries | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1743 | General or Neuraxial Anesthesia | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1940 | Immunocompromised Conditions | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2262 | CABG Surgeries | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2328 | Immunocompromised Conditions I10 | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2343 | Immunocompromised Conditions | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2363 | Creatinine Lab Test | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3011 | Acute Myocardial Infarction | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3024 | Acute Myocardial Infarction | active | 2016-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 | Encounter Inpatient | active | 2020-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.335 | Bone Marrow Transplant | active | 2021-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.336 | Bone Marrow Transplant | active | 2024-01 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.404 | Bone Marrow Transplant | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.623 | Acute Myocardial Infarction | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 | CABG Surgeries | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.737 | PCI | active | 2018-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.747 | Endotracheal Intubation | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.128 | Bipolar Disorder | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2433 | Delivery | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2435 | HBsAg | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.246 | Personality Disorder Emotionally Labile | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.247 | Personality Disorder Emotionally Labile | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.248 | Personality Disorder Emotionally Labile | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.249 | Personality Disorder Emotionally Labile | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.254 | Dysthymia | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.256 | Dysthymia | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.257 | Dysthymia | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.262 | Deceased | active | 2014-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.263 | PHQ 9 and PHQ 9M Tools | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 | Hepatitis B | active | 2017-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.271 | Hepatitis B | active | 2017-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.272 | Hepatitis B | active | 2023-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.273 | Live Birth or Delivery | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.274 | Live Birth or Delivery I10 | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.275 | Live Birth or Delivery | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.277 | Delivery | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.278 | Delivery - Diagnosis | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.279 | HBsAg | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.281 | HBsAg | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.43 | Bipolar Disorder | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.44 | Bipolar Disorder | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.45 | Bipolar Disorder | active | 2022-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.82 | Delivery | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.721 | Deceased | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.723 | PHQ-9 Tool | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1000 | Estimated Glomerular Filtration Rate | active | 2024-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1002 | Urine Albumin Creatinine Ratio | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1000 | Estimated Glomerular Filtration Rate | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1007 | Urine Albumin Creatinine Ratio | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1000 | Strabismic Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1001 | Strabismic Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1002 | Refractive Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1003 | Refractive Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1004 | Routine Ophthalmological Examination | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1005 | Pediatric Best Corrected Visual Acuity Exam | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1006 | LogMAR Visual Acuity Exam | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1007 | Aphakia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1008 | Aphakia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1009 | Infantile and Juvenile Cataract | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1010 | Infantile and Juvenile Cataract | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1011 | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1012 | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1013 | Eyelid or Orbital Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1014 | Eyelid or Orbital Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1015 | Coloboma of Optic Disc | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1016 | Coloboma of Optic Disc | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1017 | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1018 | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1019 | Optic Nerve Hypoplasia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1020 | Optic Nerve Hypoplasia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1021 | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1022 | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1023 | Cortical Blindness | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1024 | Cortical Blindness | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1025 | Congenital Condition of Retina | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1026 | Congenital Condition of Retina | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1000 | Strabismic Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1001 | Refractive Amblyopia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1002 | Routine Ophthalmological Examination | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1003 | Pediatric Best Corrected Visual Acuity Exam | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1004 | LogMAR Visual Acuity Exam | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1005 | Aphakia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1006 | Infantile and Juvenile Cataract | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1007 | Congenital Corneal or Anterior Segment Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1008 | Eyelid or Orbital Conditions | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1009 | Coloboma of Optic Disc | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1010 | Hemorrhage of Optic Nerve Sheath | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1011 | Optic Nerve Hypoplasia | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1012 | Disorder of Visual Cortex Due to Underlying Condition | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1013 | Cortical Blindness | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1014 | Congenital Condition of Retina | active | 2019-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.2 | Allergy and Intolerance Type | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.8 | Severity | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.2 | Problem Type (SNOMEDCT) | active | 2025-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.4 | Problem | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11 | Medication Product Form | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7 | SPL Drug Route of Administration Terminology | active | 2024-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.9 | Body Site Value Set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16 | Medication Brand Name | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.17 | Medication Clinical General Drug | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.18 | Medication Drug Class | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.22 | CVX Vaccines Administered Complete Set | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.28 | Procedure | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.60 | Social History Type (SCT) | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.62 | Vital Sign Result Type | active | 2024-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.64 | Medication Fill Status | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.68 | Problem Status | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.2.575 | Race Categories | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.3.155 | Care Team Category | active | 2024-06 |
| us.nlm.vsac | R4 | http://hl7.org/fhir/ValueSet/event-timing | EventTiming | active | 2023-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.1 | Detailed Ethnicity Including Absence Reasons | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.3 | Ethnicity Categories | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.14 | Clinically Important Bacteria and Fungi | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.280 | NHSNGenotypicTests | active | 2024-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.281 | Bacterial Skin Commensals | active | 2024-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1066 | Healthcare Provider Taxonomy | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3180 | NHSNInsertionSiteCode | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3181 | NHSNRoleOfPerformerCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3182 | NHSNReasonForInsertionCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3183 | NHSNSkinPreparationCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3184 | NHSNSterileBarrierCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3185 | NHSNCatheterTypeCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3194 | NHSNSignificantPathogenCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3195 | NHSNCriterionOfDiagnosisCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3196 | NHSNInfectionConditionCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3234 | NHSNPopulationCategoryCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3247 | NHSNTimingCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3248 | NHSNEligibilityCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3249 | NHSNSpecimenTypeCode | active | 2025-02 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3283 | NHSNOrganismASTCode | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3360 | NHSNAntimicrobialAgentAURPCode | active | 2025-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3361 | NHSNRouteOfAdministrationAURPCode | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 | Payer Type | active | 2025-04 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3595 | NHSNPopulationSummaryReportTypeCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6007 | NHSNVascularAccessTypeCode | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6008 | NHSNSuspectedSourceTypeCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6042 | NHSNVascularAccessSiteCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6051 | NHSNClosureTechniqueCode | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6074 | NHSNStaphAureusTestResults | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7160 | NHSNStaphAureusSpecificTest | active | 2020-07 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7214 | NHSNSameDayOutcomeMeasure | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7215 | NHSNInfectionFirstReportedSource | active | 2022-03 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7232 | NHSNRaceCategory | active | 2020-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7233 | NHSNPreviousPatientLocation | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7237 | NHSNBloodCollectionLocation | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7238 | NHSNPreviousFacility | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7239 | NHSNContraindicationType | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7240 | NHSNCarbaTestMethod | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7241 | NHSNCarbaDetectType | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7242 | NHSNCdiffTestMethod | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7338 | NHSNStartOrContinuation | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7353 | NHSNSummaryBloodProductUsage | active | 2020-08 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.836 | Race | active | 2012-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.837 | Ethnicity | active | 2012-10 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.877 | Detailed Ethnicity | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4067 | MRI of the Breast | active | 2024-06 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4068 | MRI of the Breast | active | 2022-05 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4069 | Intraspinal Abscess | active | 2022-09 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.113883.3.67.1.101.3.2444 | Major Depression Including Remission | active | 2021-02 |
| fhir.argonaut.questionnaire | R3 | CapabilityStatement/adaptive-questionnaire-service | Argonaut Adaptive Questionnaire Service CapabilityStatement | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | CapabilityStatement/answerbank | Argonaut Answerbank CapabilityStatement | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | CapabilityStatement/argo-questionnaire-provider-ehr | Argonaut Argo Questionnaire Provider Ehr CapabilityStatement | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | CapabilityStatement/assessmentbank | Argonaut Assessmentbank CapabilityStatement | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | ImplementationGuide/argonaut.us.questionnaire-1.0.0 | Argonaut Questionnaire | draft | |
| fhir.argonaut.questionnaire | R3 | OperationDefinition/next-question | Argonaut Next Question Operation | draft | 2018-08 |
| fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-audit-c | Alcohol Use Disorder Identification Test - Consumption [AUDIT-C] | draft | 2019-02 |
| fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-dast | Drug Abuse Screening Test-10 [DAST-10] | draft | 2018-07 |
| fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-housing | Housing Questions | draft | 2018-07 |
| fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-phq9 | Patient Health Questionnaire (PHQ-9) | draft | 2018-07 |
| fhir.argonaut.questionnaire | R3 | Questionnaire/questionnaire-example-sampler | Argonaut Questionnaire Sampler | draft | 2018-07 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context-type-value | context-type-value | draft | 2018-12 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context-type | context-type | active | 2018-12 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-context | context | draft | 2018-12 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-publisher | questionnaire_publisher | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-status | questionnaire_status | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-title | questionnaire_title | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/Questionnaire-version | questionnaire_version | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-author | questionnaireresponse_author | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-context | questionnaireresponse_context | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-patient | questionnaireresponse_patient | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-questionnaire | questionnaireresponse_questionnaire | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-source | questionnaireresponse_source | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/QuestionnaireResponse-status | questionnaireresponse_status | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | SearchParameter/patient-birthdate | patient_birthdate | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-adap-questionnaireresponse | Argonaut Adaptive QuestionnaireResponse Profile | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaire-valueset | Argonaut Questionnaire Contained ValueSet Profile | active | 2018-05 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaire | Argonaut Questionnaire Profile | active | 2018-04 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/argo-questionnaireresponse | Argonaut QuestionnaireResponse Profile | active | 2018-04 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-itemOrder | Argonaut Questionnaire Item Order Extension | active | 2019-02 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-multipleAnd | Argonaut SearchParameter Multiple AND Extension | active | 2018-04 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-multipleOr | Argonaut SearchParameter Multiple OR Extension | active | 2018-04 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-responsePeriod | Argonaut QuestionnaireResponse Response Period Extension | active | 2018-04 |
| fhir.argonaut.questionnaire | R3 | StructureDefinition/extension-timeLimit | Argonaut Questionnaire Time Limit Extension | active | 2018-02 |
XIG built as of 23 Jun 2025. Found 77207 resources in 1238 packages.
FHIR